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ABSTRACT
Several methods for the preparation of novel substituted methylene- 
bisphosphonates were examined. A new synthesis of monofluoromethylene- 
bisphosphonic acid was developed involving the in situ nucleophilic 
debromination of tetraisopropyl bromofluoromethylenebisphosphonate. The 
Michael reaction of tetraalkyl ethenylidenebisphosphonates with 
alkanethiols was shown to be a facile method of preparation of C- 
(thioalkyl)methyl methylenebisphosphonates. Tetraisopropyl cyclo­
propane-1 ,1-bisphosphonate was synthesised via an intramolecular alkyl­
ation of a thallium(I) salt. Thallium(I) salts of methylenebisphos­
phonates were also used in the synthesis of bisphosphonates related to 
arildone.
The reaction of trialkyl phosphites with thiophosgene was 
investigated and it was shown that in THF at low temperature thio- 
carbonylbisphosphonate was not formed but that phosphorus stabilised 
ylids were the principal products.
The bisphosphonates prepared were tested for inhibitory effect 
against the RNA polymerase of influenza A/X49; bisphosphonates with 
electron-withdrawing bridge substituents showing most inhibition. 
Selected bisphosphonates were found to have slight activity against the 
reverse transcriptase of HTLV-III; the causative agent of AIDS.
CHAPTER 1
INTRODUCTION
Until the end of the 19th century most diseases were thought to be 
bacterial or fungal in origin. In 1898 it was deaonstrated that after 
an infectious solution of foot and mouth disease was passed through a 
fine filter; capable of withholding the smallest bacteria, the filtrate 
regained infectious (Loeffler and Frosch, 1898). Thus the viral nature 
of this disease was shown. Siailar experiments were carried out by 
Beijerinck (1899) who introduced the tern "virus'* for the causative 
agent of tobacco mosaic disease which was shown to be viral in the same 
manner.
In 1917 Twort identified viruses which infect bacteria 
(bacteriophages) and viruses are now known which infect most forms of 
life. They have been discovered to infect insects (Bergold, 1958), 
fungi (Hollings, 1962), algae (Schneider, et al, 1964) and protozoa 
(Diamond, et al, 1972). They are now known to be responsible for many 
diseases of man, e.g. acquired immune deficiency syndrome (AIDS) and 
influenza, for which little in the way of vaccines or chemotherapy is 
currently available.
Viral reproduction is governed by the availability of suitable 
cells which can be attacked. Once this occurs the cells' nucleic acid 
synthesis mechanisms are diverted to produce viral nucleic acid. New 
virions are assembled inside the cell and are released by budding 
through the cell wall. This intimacy of viral and cellular reproduction 
is responsible for the lack of viable treatments available against viral 
infection.
1.1 INFLUENZA VIRUS
Influenza virus possesses a most unusual RNA polymerase activity 
which is primed by a capped oligonucleotide cleared from cellular mRNA. 
The virus has been extensively studied in the search for methods of
inhibition and in the viral life-cycle interruption of the RNA 
polymerase activity is one possibility.
1.1.1 Influenza Virion Structure
Influenza viruses consist of about 70% protein, 25% lipid, 4% 
carbohydrate and 1% single-stranded RNA. New virions are formed by
budding out of an infected cell and are usually spherical with a 
diameter of about lOOnm although other shapes do exist. The RNA is 
associated with the nucleoprotein (NP) to form an ordered filamentous 
structure called the ribonucleoprotein (RNP). This is surrounded by a 
6nm thick layer of matrix protein, which is almost one third of the mass 
of the virion (White, et al, 1970), and a viral envelope. This is a 
lipophilic bilayer which gives additional protection to the virion 
(White. 1973), (Fig. 1.1.1).
From the surface of the viral envelope project several thousand 
glycoprotein spikes which can be divided into two classes; the
haemagglutinins (HA) and the neuraminidases (NA) whose functions are 
described later (sections 1.1.2.1 and 1.1.2.3). The ratio of these has 
been found to vary greatly in different strains of influenza (Webster, 
1968).
Polyacrylamide gel electrophresis of influenza virus RNA indicates 
eight fragments in the range 890-2341 nucleotides in length (McGeoch, et 
al, 1976). Segments 1, 2 and 3 code for the proteins PBi , PB2 and PA 
(Palese, et al, 1977). Segment 4 codes for the haemagglutinin (HA). 
Segment 5 codes for the nucleoprotein (NP) which in combination with the 
RNA forms the ribonucleoprotein (RNP) (Compans, et al, 1972). Segment 6 
codes for the neuraminidase (NA). Segment 7 codes for two proteins; Mi 
(the matrix protein) and Ht and segment 8 codes for the proteins NSi and 
NS*. The functions of these final two proteins along with N* have not 
been determined although NSi may be involved in inhibiting host cell 
protein synthesis (Lamb, 1983).
2
Fig. 1.1.1 The structure of the influenza virion.
1.1.2 Infectious Cycle of Influenza
1.1.2.1 Initial Stages of Infection
The first stage of infection occurs when a virion attaches itself 
to a suitable receptor site on the surface of the cell plasma membrane. 
For influenza the receptor site was discovered to be a glycoprotein 
containing X-acetylneuraminic acid (sialic acid) (Gottschalk, et al, 
1972). The function of the haemagglutinin spikes is to attach the 
virion to the N-acetyl neuraminic acid residue at a susceptible site so 
that infection nay be initiated (Nayak, 1977). The viral envelope then
3
fuses with the cell plasma membrane, the virion uncoats and the 
nucleocapsid is injected into the cytoplasm. Fusion with the plasma 
membrane occurs rapidly at 37#C (Morgan and Rose, 1968). These 
processes are not well understood and it is probable that virions also 
enter the cell by other processes such as pinocytosis and phagocytosis.
1.1.2.2 RMA Synthesis
Influenza virus expresses an RNA dependent RNA polymerase activity 
which is retained in purified samples of ribonucleoprotein (RNP) 
indicating that one or more of the core proteins are responsible 
(Compans and Caliguri, 1973). This is now known to be the case. The 
synthesis of viral RNA may be divided into primary and secondary 
transcription.
1.1.2.2.1 Primary Transcription
This results in the synthesis of viral mRNA and is begun by 
cleavage, at a purine residue, of a capped oligonucleotide of 10-13 
bases in length from cellular mRNA. This oligonucleotide acts as a 
primer for the initiation of viral mRNA synthesis which is then found to 
continue according to the template sequence (Lamb and Choppin, 1983) 
(Fig. 1.1.2.2.1(a)). These processes are carried out by the RNA
polymerase complex which consists of PBi (the smaller basic protein), 
PB* (the larger basic protein), PA (the acidic protein) and NP (the 
nucleoprotein) with a total molecular weight of 255,000 (Winter and 
Fields, 1982) (Fig. 1.1.2.2.1(b)).
CLEAVAGE endonucleolytic cleavage
m7GpppXmY_..................... ^IpZ
m7GpppXmY........................GlpZ
10-13 nuclotides
INITIATION
,  UpÇpGpUpUpUpUpCp..__
m^GpppXmY............A '------Gppp
ELONGATION
UpÇpGpUpUpUpUpCp....... .
m^GpppXmY..................ÂpGpCpÂpÀpÂpApGp......
Fig. 1.1.2.2.1(a) Initiation of influenza viral RNA synthesis (Krug, 1983)
It is known that the PB2 protein recognises the 5* end of the 
cleaved oligonucleotide priner and binds to it (Krug, 1983). It is 
suggested that PB2 becomes dissociated from the 5* end of the primer 
again after the addition 11-15 nucleotides (Braam, et al, 1983). The 
protein PBi is involved in initiating transcription and appears to be 
responsible for directing the addition of each incoming nucleotide to 
the growing mRNA chain (Braam, et al, 1983). Specific roles in the 
process for the proteins PA and NP have not been determined. When
5

to associate with these areas and a new virion is formed by budding of 
the plasma membrane (Compans and Dimmock, 1969).
Exactly how the ribonucleoprotein is packaged remains unclear. 
The probability of selection of the correct eight fragments of RNA by 
chance is unrealistically small. It has been proposed that the viral 
RNA is associated into one continuous strand and that the known 
fragments are due to weak points between the individual sections (Pons, 
1970) .
Finally the new virion is released from the cell. This is 
expedited by the neuramininidase spikes. The neuraminidase enzyme 
hydrolyses the bond between N-acetylneuraminic acid and its adjacent 
carbohydrate. This removes the N-acetylneuraminic acid from the budding 
region and so there is no binding site for the haemagglutinin (Klenk, 
1974) .
1.1.3 Influenza Antigenicity
Human influenza viruses represent an intriguing problem to 
preventative medicine because their antigenicity is constantly changing. 
Changes in viral surface proteins can occur such that the virus is no 
longer recognised by the immune system.
An antigenic shift is where a drastic change in surface proteins 
occurs. There is evidence that this results from gene exchange when two 
different strains of influenza infect the same cell. This process has 
been observed between both animal (Gardner and Shortridge, 1979) and 
human (Bean, et al, 1980) strains of influenza. The most striking 
example of the results of antigenic shift occurred in 1918-1919 when an 
influenza epidemic was responsible for the deaths of over twenty million 
people.
1.1.4 Influenza Vaccines
Incubating influenza virus suspensions in formalin for long 
periods results in a loss of infectiousness but not of antigenicity 
(Gard, 1960). This technique has been developed for preparing 
inactivated virus suspensions for use as vaccines but doubts have been 
expressed as to the efficacy, of this approach if there is a poor 
antigenic match (Hoskins, et al, 1978) with the new strain of influenza.
Attempts have been made to prepare vaccines from live attenuated 
virus by various means but it has been shown that only small antigenic 
shifts are required for a great reduction in immunity to occur (Wang, 
1983). There is also the risk in live virus preparations of the 
presence of other viruses causing further infection.
The continually changing antigenicity of influenza means that new 
vaccines have continually to be developed and thus they have only seen 
use in select high risk sections of the population. Vaccines can only 
play a prophylactic role and are of little use once infection has begun.
1.2 Antiviral Chemotherapy
In view of the problems with vaccines and the lack of treatment 
currently available after infection has started many classes of 
compounds have been examined for antiviral activity but the number in 
clinical use is very small. The approach taken has been to try and 
inhibit virus specific processes such as uncoating or nucleic acid 
synthesis (Smith, et al, 1980).
A good example is provided by 9-(2-hydroxyethoxymethyl)guanine 
(acyclovir. Fig. 1.2) which is now in clinical use. It is a very 
effective inhibitor of herpes and other DNA viruses and has low 
toxicity. Only in herpes infected cells is acyclovir phosphorylated and 
the triphosphate competes with GTP for the viral DNA polymerase.
0Fig. 1.2 Hie structure of acyclovir
The very snail number of clinical antiviral drugs contrasts 
starkly with the vast range of antibacterial compounds in clinical use. 
This is because an easy target is bacterial cell wall biosynthesis. 
Inhibiting this is the mode of action of the penicillins and 
cephalosporins (Tomas*. 1979). Some of the more effective compounds 
against influenza are discussed below.
1.2.1 Amantadine And Rimantadine
(1) (2 )
Fig. 1.2.1 Hie structures of amantadine (1) and rimantadine (2)
Amantadine and rimantadine (Fig. 1.2.1) are now well established 
in the treatment of influenza (Oxford and Galbraith, 1980). Amantadine 
was licensed for use in the USA in 1966 and rimantadine is available 
clinically in the USSR (Zlyndikov, et al, 1981). Their mode of action 
has been investigated and appears to be involved in viral uncoating 
(Kato and Eggers, 1969). In the presence of amantadine no transcription 
of viral RNA can be detected (Tilley and Kramer, 1981).
In spite of this the clinical use of amantadine has been 
restricted for several reasons. It is only really effective against 
enveloped viruses such as influenza and has side effects such as 
insomnia and hallucinations. These are indicative of a secondary effect 
on the central nervous system. Other lipid soluble amines show similar 
effects to amantadine (Hay and Zambon, 1984). It has also been reported 
that when amantadine was used against influenza in the lungs of nice, 
resistant strains of virus were found to develop (Oxford, et al, 1970).
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Rimantadine has been reported to be more effective than amantadine 
against influenza (Schulman, 1968) and also demonstrates reduced side 
effects (Oxford, 1984). This has led to its more widespread use. In 
prophylactic use both of these are almost totally effective in 
preventing clinical illness. Although administration within 48h post 
infection does not halt the infection, fever symptoms can be reduced 
(Dolin, et al. 1982).
1.2.2 Ribavirin and Analogues
Ribavirin (Fig. 1.2.2) expresses a broad spectrum of activity 
against a range of viruses, including influenza, both in cell culture 
and animals (Allen, et al, 1978; Browne, 1979). It is known to inhibit 
the synthesis of viral mRNA in influenza where in vivo the active 
species is probably the triphosphate. Ribavirin 5*-triphosphate is an 
inhibitor of influenza RNA polymerase in vitro under conditions where 
neither ribavirin or ribavirin 51 -monophosphate show any activity 
(Eriksson, et al, 1977). However ribavirin 5; -monophosphate is known to 
be a potent inhibitor of IMP dehydrogenase which is involved in the 
biosynthesis of GMP and this may be important in its action against 
viruses other than influenza (Oxford, 1975).
In animals ribavirin is effective in reducing mortality and fever 
symptoms even if given as late as 72h after initiation of infection 
(Chen, et al, 1983). However the clinical use is limited as the 
compound is teratogenic.
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Fig. 1.2.2 The structures of ribavirin (3) and selenazofurin (4)
Various analogues have been examined for activity where other 
atoms are included in the heterocyclic ring and selenazofurin has been 
found to be a good inhibitor of influenza (Sidwell, et al, 1985) being 
more effective than ribavirin although it is cytotoxic.
1.2.3 Metal Ion Chelators As Antiviral Agents
1.2.3.1 Involvement of Metal Ions
The presence of metal ions in both RNA and DNA polymerases has 
been well documented (Mildvan and Loeb, 1979; Perrin and Stiinzi, 1981). 
The effects of these ions have been examined and different metal ions 
exert both structural and catalytic roles. Many enzymes in both 
infected and uninfected cells require metal ions for activity (Williams, 
1983) and indeed the suggestion has been made that all nucleotidyl 
transferases are in fact metalloenzymes (Valenzuala, et al, 1973). The 
presence of these metal ions suggests the possibility of inhibiting 
viral enzymes by the use of chelating agents to coordinate to essential 
metal ions.
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Zinc ions in particular appear to have a catalytic role in some 
nucleic acid polymerases (Coleman, 1984), having been found to be 
present in the RNA polymerase of Escherichia coli in 1971 (Scrutton, et 
al, 1971). A role for zinc in nucleic acid synthesis was proposed, as 
removal of zinc ions from the DNA polymerase of the same organism by the 
chelating agent 1,10-phenanthrol'ine led to loss of polymerase activity 
which was restored by the addition of zinc ions to the apoenzyme 
(Springgate, et al, 1973). In the case of the bacteriophage T? RNA
polymerase the activity of the enzyme was found to correlate 
approximately with the zinc content (Coleman, 1974).
In the case of influenza virus the RNA polymerase activity is 
known to be dependent on the presence of zinc ions (Oxford and Perrin, 
1977) and a correlation has been found between the ability of 
pyrophosphate analogues to bind zinc and their in vitro antiviral 
activity (Cload and Hutchinson, 1983).
1.2.3.2 Thiosemicarbazones
The first report of a thiosemicarbazone with antiviral activity 
was that p-aminobenzaldehyde thiosemicarbazone (Tig. 1.2.3.2 (5)) had 
activity against vaccina virus (Hamre, et al, 1950). The related 
compound (6) will inhibit the replication of herpes viruses type 1 and 2 
in vitro (Shipman, et al, 1981) and also influenza virus (Oxford and 
Perrin, 1974).
The mode of action of these compounds probably involves metal ion 
chelation. Thiosemicarbazones are good chelators of metal ions and in
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Fig. 1.2.3.2 ,nuose»icarbazcnes with antiviral activity
the case of compound (6) and its isomers only the 2-substituted isomer 
shows any activity against influenza. It has been proposed that this 
may be due to formation of a terdentate complex with an essential zinc 
ion which is not possible for the 3- and 4-substituted isomers (Oxford 
and Perrin, 1974).
1.2.3.3 Other Chelating Agents
Several metal chelating compounds which are used industrially in 
metal ion extraction (Burger, 1973) have been found to possess antiviral 
activity against influenza in vitro (Hutchinson, 1985) but not in vivo. 
This is probably due to their polarity preventing their crossing of cell 
walls (Oxford and Perrin, 1977).
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Fig. 1.2.3.3 Hie structures of (7) ECTTA, (8) 1,10-phenanthroline, (9) bathocuprin
disulphcnic acid
Ethylenediamine tetraacetic acid (EDTA; Fig. 1.2.3.3 (7)) is found 
to inhibit the neuraminidase activity of influenza viruses of the N1 
serotype. This enzyme has an absolute requirement for calcium ions 
(Dimmock, 1971) with which EDTA can form strong complexes. 1,10- 
phenanthroline (Fig.1.2.3.3. (8)) and bathocuprin disulphonic acid (Fig.
1.2.3.3 (9)) inhibit in vitro the RNA polymerase activity of influenza 
(Oxford and Perrin, 1974) but relatively high concentrations of these
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have no detectable effect on the haemagglutinin, neuraminidase or 
infectivity of influenza and are inactive in animals (Oxford and Perrin, 
1977).
Fig. 1.2.3.4 (10) Owsphcnofomiic acid, (11) Phosphcnoaoetic acid, (12)
Car bony lbisphosphonic acid
Interest in this class of compounds was initiated by the report 
that phosphonoacetic acid (Fig. 1.2.3.4 (11)) was found to inhibit 
herpes viruses in animals (Shipkowitz, et al, 1973); having been 
discovered in a random screen. It was subsequently demonstrated that 
phosphonoacetic acid was active against herpes viruses, in tissue 
culture, under conditions where cell nucleic acid synthesis was little 
affected (Overby, et al, 1974). It was recognised that the activity of 
phosphonoacetic acid was due to inhibition of a herpes induced DNA 
polymerase in infected cells (Leinbach, et al, 1976).
1.2.3.4 Pyrophosphate Analogues
o o o o
ii ii ii ii(H0)2P----- C— OH (HOljP CH— C— OH
( 10) (11)
(12)
1<
Extensive structure-activity studies have been carried out on 
phosphonoacetic acid for the inhibition of herpes in vitro (Mao, et al, 
1985) and these demonstrate strict requirements for activity. 
Monoesterification of the phosphono group results in retention of only 
slight activity and others (Eriksson, et al, 1980) report no significant 
activity for monoesters of phosphonoacetic acid. Di- and 
triesterification results in loss of in vitro activity although a recent 
report indicates some in vivo activity (Mao, et al, 1985).
Insertion of one or more methylene units results in a loss of 
antiviral activity but removal of the one methylene unit present to give 
phosphonoformic acid (Fig. 1.2.3.4 (10)) gives a compound of good anti­
herpes activity (Eriksson, et al, 1982). Phosphonoformic acid is also 
found to be a good inhibitor of influenza viruses (Stridh, et al, 1979) 
where it is found to inhibit chain elongation in viral RNA synthesis 
(Stridh and Datema, 1984).
1.3 Mode of Action of Pyrophosphate Analogues Against Influenza
The mode of action of pyrophosphate analogues has been extensively 
studied and it is now clear that they act without prior metabolism and 
inhibit the RNA polymerase of influenza, probably via chelation to an 
essential zinc ion. The influenza RNA polymerase has been shown to be 
zinc requiring (Oxford and Perrin, 1977) and there is a correlation 
between the ability of pyrophosphate analogues to bind zinc under 
physiological conditions and their in vitro activities against influenza 
(Cload, 1983).
Against influenza monothiopyrophosphoric acid (Fig. 1.3(a)(13) and 
dithiopyrophosphoric acid (Fig.1.3. (a) (14)) are found to exhibit a 
greater activity than their fully oxygenated analogue (Hutchinson, ef 
al, 1985). Thiophosphonoacetic acid (Fig. 1.3(a) (15)) shows a greater 
activity than phosphonoacetic acid (Hutchinson and Masson, 1986).
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Fig. 1.3(a) Sulphur containing pyrophosphate analogues (13) McnotMopyrophosphoric 
acid, (14) Dithiopyrophosphoric acid, (15) Thiophosphonoacetic acid.
The increased activity appears to be related to the increased 
ability to bind zinc. The greater affinity of sulphur towards zinc 
under the Pearson rules for hard and soft acids and bases (Pearson, 
1966) results in the thiopyrophosphate analogues forcing stronger 
complexes with zinc than their fully oxygenated counterparts 
(Hutchinson, et al, 1985). Addition of metal ions to aqueous solutions 
of pyrophosphoric acid and bisthiopyrophosphoric acid and examination by 
*‘P NMR spectroscopy indicates that bisthiopyrophosphoric acid binds to 
"soft" zinc ions through sulphur and "hard" magnesium ions through 
oxygen (Hutchinson, et al, 1985). Nucleoside thiophosphates have been 
shown to complex to cadmium ions through sulphur (Pillai, et al, 1980) . 
These compounds (Fig. 1.3.(a)(13), (14), (15)) are also of interest
because of their apparent low toxicity to cells (Hutchinson, et al, 
1985).
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There i* **so evidence that pyrophosphate analogues act directly 
on the viral RNA polyaerase fr0a enzyme kinetic studies, in the case of 
the herpes DNA polyaerase phosphonoacetic acid and pyrophosphoric acid 
have been shown to coapete for the same binding site (Leinbach, et al. 
19?6). Also in the case 0f influenza virus phosphonoforaic acid is 
found to have no effect on the initiation of viral mRNA synthesis but 
that the chain elongation step i, prevented (Stridh and Dateaa, 19S4).
In the case of herpes viruses the suggestion has been made that 
Pyrophosphate analogues inhibited the viral DNA polymerase after 
■etabolisa to nucleoside triphosphates which then act as coapetitive 
inhibitor« to the natural substrates (Leinbach.ef al. 1976). Tor 
influenza this does not seem likely for a number of reasons. Ribo- and
•^9*1.3(b) Nucleoside triphosphate analogues with the P . T -residues replaced by 
(16) dichlcrcmethylenebisphosphauc ecid, (17) phosphonoacetic acid
BASE
OH OH
(16)
(17) OH OH
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deoxyribonucleoside triphosphate analogues have been synthesised with 
the P, 1 -phosphoryl residues replaced by dichloromethylene-
bisphosphonic acid and phosphonoacetic acid (Cload, 1983) (Fig. 1.3(b)). 
These were found not to interact with the RNA polymerase of influenza 
virus (Cload and Hutchinson, 1983).
Phosphonoformic acid is a good inhibitor of the influenza RNA 
polymerase (Cload and Hutchinson, 1983) but nucleotide analogues of 
phosphonoformic acid cannot be prepared by standard methods and there is 
evidence that they are very unstable (Hutchinson, et al. 1983). Finally 
when [3H]-labelled phosphonoacetic acid was incubated with detergent 
disrupted suspensions of influenza, under conditions of limited nucleic 
acid synthesis, no labelled nucleotide analogues were formed (Cload and 
Hutchinson, 1983).
1.4 Clinical Use Of Pyrophosphate Analogues
At present the clinical use of pyrophosphate analogues is very 
limited. In animal models phosphonoacetic acid has shown toxic effects 
(Boezi, 1979) and skin irritation (Eriksson and Oberg, 1984). 
Phosphonoformic acid has undergone clinical trials against a range of 
viruses and most recently shown benefit in compassionate use for 
severely immunocompromised AIDS patients (Oberg. et al. 1987). The 
reasons tor their limited clinical use are twofold; problems associated 
with their facile adsorption by bones and teeth, and difficulties in 
crossing cell membranes. Each of these are discussed below.
1.4.1 Adsorption By Bones
A major problem limiting the clinical use of pyrophosphate 
analogues is that they have a great affinity for calcified tissue and 
are readily adsorbed by bones and teeth (Fleisch and Telix, 1979). On 
administration they are rapidly cleared from the blood and accumulate in 
calcified tissue. On administration of [**C]-labelled dichloromethylene-
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bisphosphonic acid to young rats the measured bone radioactivity reached 
a maximum in only thirty minutes (Mdnkkdnen, et al, 1987). This is due 
to the binding of the bisphosphonic acid and not of any metabolites as 
it is known that dichloromethylenebisphosphonic acid is not metabolised 
in rats (Fleisch, 1983). Although highly undesirable for an antiviral 
compound this ability has led to other therapeutic uses.
\ \ j
(HO) P------C
2 I 2
OH
(19)
Fig. 1.4.1(a) Diphosphonates used to treat Paget’s disease (18)Dichloranethylene- 
bisphosphcnic acid (19) Ethane-l-hydroxy^l, 1-bisphosphcnic acid
Dichloromethylenebisphosphonic acid (Fig. 1.4.1(a) (18)) and 
ethane-l-hydroxy-l,l-bisphosphonic acid (Fig. 1.4.1(a)(19) are found to 
inhibit the aggregation and dissolution of calcium phosphate crystals 
and this has led to their use in regulating bone turnover in Paget's 
disease (Francis and Centner, 1978).
Diphosphonates are commonly complexed with technetium-99 and the 
resulting complexes are found to be excellent bone imaging agents (eg 
Wang, et al, 1980). These however lack the specificity which might 
allow treatment of bone tumours (Spencer and Hosain, 1986). Three of 
the most commonly used diphosphonates are shown below (Fig. 1.4.1(b)).
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Fig. 1.4.1(b) Diphosptonates used in bene imaging (20) Carixxiylbisphosphonic acid, 
(21) Hydrcocymethylenebisphcnonic acid, (22) fethylenebisptositonic 
acid
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1.4.2 Crossing Cell Membranes
A second major drawback is that cells do not readily take up small 
highly charged molecules because of the presence of a lipid cell wall. 
High plasma concentrations of pyrophosphate analogues are thus often 
required to be effective in vivo.
Nucleoside esters of phosphonoacetic acid have shown antiviral 
activity in tissue culture (Heimer and Nussbaum, 1977) and esters of 
phosphonoformic acid have shown antiherpes activity in tissue culture 
(Noren, et al, 1983). The mode of interference of these compounds is 
not clear but it is possible that because of their increased 
lipophilicity they are absorbed more readily and are hydrolysed inside 
the cell to yield their parent acids. This behaviour as pro-drugs is 
not unreasonable as the presence of esterases in cells has been well 
documented (eg Stryer, 1975).
1.5 Outline of Work Undertaken
The aim of the present work was to investigate the preparation of 
novel substituted methylenebisphosphonates and to examine the activities 
of a broad range of these compounds against the RNA polymerase of 
influenza virus A/X49. It was hoped that this would lead to a better 
understanding of the features required for effective inhibition of the 
RNA polymerase activity and enable new compounds to be developed which 
are more active against influenza virus than those currently available.
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CHAPTER 2
SYNTHESIS OF FLUORINATED HETHYLENEBISPHOSPHONATES
2.1 Introduction
2.1.1 The Arbuzov and Michaelis-Becker Reactions
The Arbuzov reaction has been of enormous synthetic value in 
organophosphorus chemistry. In its simplest form a trialkyl phosphite 
reacts with an alkyl halide via two successive Sn 2 processes to yield a 
dialkyl phosphonate (Fig. 2.1.1(a)) (Bhattacharya and Thyagarajan, 
1981).
Fig. 2.1.1(a) The Arbuzov reaction
The first step of the reaction is the formation of an intermediate 
phosphonium salt which can be isolated if the leaving group is a weak 
nucleophile (Colle and Lewis, 1978). Arbuzov (1910) originally 
postulated the formation of a pentacoordinate intermediate. Bodkin and 
Simpson (1972) suggested that a pentacoordinate intermediate was formed 
in the reaction and studies on the dealkylation step by Hichalski 
(Hichalski, et al, 1978) give some evidence for an equilibrium between 
the two species. In the second step of the reaction both Sn 2 and Sn 1
R— X
X >Cl,Br,I
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mechanisms appear possible depending on the alkyl group (Griffiths and 
Berg, 1962).
The Arbuzov reaction does not normally require catalysis but in 
special cases catalysis is reported to be effective. Arbuzov reactions 
of unsaturated alkyl halides are reported to be accelerated by the 
addition of palladium chloride (Tavs and Korte, 1967) and reactions of 
halobenzenes may be photocatalysed (eg Kyba, et al. 1983; appendix I).
In the synthesis of phosphonates only one of the alkoxy residues 
of the trialkyl phosphite participates in the reaction, thus the 
reaction may be used directly in the synthesis of phosphinates and 
phosphine oxides. These variations of the reaction were developed by 
Nichaelis (1903). Sodium salts of dialkyl phosphites are found to react 
with alkyl halides to yield the same product and this reaction has 
become known as the Michaelis-Becker reaction (Hichaelis and Becker, 
1897) (Fig. 2.1.1(b)).
Fig. 2.1.1(b) The Michaelis-Becker reaction
This reaction has also been extensively used in synthesis with the 
diethyl ester normally being the ester of choice. With halobenzenes the 
Michaelis-Becker reaction may be photocatalysed (Bunnett and Creary, 
1974). The presence of a negative charge on the nucleophile causes an 
increased reactivity and often alkyl chlorides may be used in cases 
where the Arbuzov reaction is too slow and the alkyl bromide would be 
the halide of choice. In this study the increased reactivity of sodium
0
(R0)2P— K' ♦ NaX
XmCl,Br,I
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diisopropyl phosphite over triisopropyl phosphite was exploited in the 
synthesis of fluorinated methylenebisphosphonates.
2.1.2 Halogenated Hethylenebisphosohonic Acids
Methylenebisphosphonic acid is found not to inhibit the RNA
polymerase of influenza virus but halogenated methylenebisphosphonic 
acids do show inhibition (Cload and Hutchinson, 1983) . The reason for 
this is proposed to be the failure of the bridge methylene unit to 
reflect the electronegativity of the bridge oxygen atom in
pyrophosphoric acid (Blackburn, 1981) with the subsequent increase in 
acid dissociation constants. Simple syntheses of dichloro- and 
dibromomethylenebisphosphonate are now well known (Quimby, et al, 1968) 
and employ the base catalysed reaction of tetraalkyl methylene-
bisphosphonate with sodium hypohalite or molecular halogen (Fig.
2.1.2(a)).
Monochlorination and monobromination of tetraalkyl methylene-
bisphosphonates are difficult to control and lead to mixtures of raono- 
and dihalogenated species which are difficult to separate (Quimby, et 
al, 1968). This has led to the development of routes for the selective 
monodeha logenat ion of dichloro- and dibromomethylenebisphosphonate. 
This can be accomplished by reaction with butyllithium (Seyferth and 
Marmor, 1973) or potassium fluoride in the presence of [18,6]crown ether 
(Hutchinson and Semple, 1984) (Fig. 2.1.2(a)).
Hata has prepared monohalogenated analogues of compounds 
containing active methylene groups by heating together mixtures of the 
unhalogenated and dihalogenated species for long periods (Hata, 1965). 
However this procedure has been found to be unsuccessful in the case of 
methylenebisphosphonates (Nicholson and Vaughn, 1971); no reaction 
being detectable by 3*P NMR.
The reduction of dichloro- and dibromomethylenebisphosphonates 
with sodium hydrosulphide has been reported to give good yields of the
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corresponding monohalogenated species (Nicholson and Vaughn. 1971) (rig. 
2.1.2(b)). The reaction probably proceeds via nucleophilic 
dehalogenation followed by reduction. The synthesis is reported to be 
unreliable (Semple, 1986) with the earlier methods for 
■onodehalogenation being preferable.
Fig. 2.1.2(a) Syntheses of halogenated methylenebisphosphonates
2.1.3 Fluorinated Hethylenebisphosphonic Acids
The anti-influenza activity of halogenated methylenebisphosphonic 
acids has led to interest in the corresponding fluorinated compounds. 
The above methods for halogénation of tetraalkyl methylene-
bisphosphonates cannot readily be adapted for fluorination, which is 
often difficult to control and unselective. The reaction of tetraalkyl 
methylenebisphosphonates with solutions of fluorine in toluene (Proctor 
and Gamble Co, 1966) is reported to be difficult to reproduce 
(Blackburn, #f al, 1981). Reaction with fluorine gas, perfluoro-
0 0
Ü ?I(R0)2P- :h (ro>2p — c x — P(OR>2
BuLi
or KF/«-CROWN-6
X = CI,Br 
R = Et,Pr'
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Fig. 2.1.2(b) The reaction of dihalagencmethylenebisphosphonates with sodium 
hydrosulphide
piperidine and perfluoro-2,6-dinethylpiperidine have all been attempted 
(Blackburn, et al, 1981) but in each case partial fluorine substitution, 
at every position in tetramethyl methylenebisphosphonate, was observed.
The electrophilic fluorinating agent perchloryl fluoride has been 
shown to fluorinate the sodium salt of diethyl malonate (Gershon, et al, 
1966) and this has prompted the use of this reagent for fluorinating 
methylenebisphosphonates (Blackburn,1981; McKenna and Shen, 1981). How­
ever these syntheses suffer from the fact that perchloryl fluoride is 
hazardous to use and also mixtures of mono- and difluoromethylene- 
bisphosphonates are formed which are difficult to separate. 
Fluorination of tetraalkyl aethylenebisphosphonates is thus not
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particularly suited to the synthesis of mono- and difluoromethylene- 
bisphosphonates. Although a-hydroxybenzylphosphonates have recently 
been shown to react smoothly with DAST (diethylaminosulphurtrifluoride, 
Middleton,1975; Markovskij, et al, 1973) to yield a-fluorobenzyl- 
phosphonates (Blackburn and Kent, 1986).
An alternative strategy • is to synthesise mono- and 
difluoromethylenebisphosphonic acids from fluorinated precursors. The 
first example of a fluorinated phosphonate was reported by Soborovskii 
and Baina (1959) prepared by the reaction of chlorodifluoromethane and 
sodium diethyl phosphite (Fig. 2.1.3(a)).
The reaction probably does not proceed via an Sn 2 mechanism but 
via positive chlorine abstraction and reaction of the resulting 
carbanion with the diethyl phosphorochloridate formed. Sn2 reactions on 
the a-carbon atom of phosphonates only occur with very good leaving 
groups such as triflates (Phillion and Andrew, 1986) .
chf2ci NaQ
Fig. 2.1.3(a) Ihe reaction of chlorodif luorcmethane with sodium diethyl phosphite
The Arbuzov reaction of trialkyl phosphites with dibromodifluoro- 
methane was reported to yield bromodifluoromethylphosphonates (Burton
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and Flynn, 1977) and this synthesis was continued with a Michaelis- 
Becker reaction to yield the first examples of tetraalkyl difluoro- 
methylenebisphosphonates (Burton and Flynn, 1980) (Fig. 2.1.3(b)). In 
the application of this route to the synthesis of unsymmetrical 
difluoromethylenebisphosphonates mixtures of difluorinated methylene- 
bisphosphonates were obtained (Fig. 2.1.3(c)). This was rationalised by 
the formation of difluorocarbene and competition between the dialkyl 
phosphite anions to trap the difluorocarbene (Burton, et al. 1982). 
Trapping of dif luorocarbene by strong bases in reactions of 
dibromodifluoromethane is known to occur (Sheppard and Shats, 1969).
In this study a one-step synthesis of tetraisopropyl 
difluoromethylenebisphosphonate was developed and the understanding 
gained used to construct a simple synthesis of monofluoromethylene- 
bisphosphonic acid which avoids the use of perchloryl fluoride.
0
(R0)3P .  CFXYj ------------ (R0)2P—  CFXY .  RY
R = Me,Et,Pr',Bu X = F,Br Y = Br
Fig. 2.1.3(b) The synthesis of tetraalkyl difluorcaethylenebisphosphcnates
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0 0
Na* -P fOBuL
BrF C^— P(OEt)2 — '
(EtO^P— CF2— P(OEt)2
0 Q
“ (EtO»2P— CF2— P(OBu)2
(BuO)2P— CF2— PKJBu^
Fig. 2.1.3(c) Hie reaction between sodiun dibutyl phosphite and diethyl 
brcmcdifluorcmethylphosphonate
2.2 Results And Discussion
2.2.1 Tetraalkyl Difluorosethylenebisphosphonates
The reported Arbuzov reaction between triisopropyl phosphite and 
dibroBodifluoromethane (Burton and Flynn, 1977) was found to be 
unsuccessful. In refluxing diethyl ether or tetrahydrofuran no reaction 
was observed and under more forcing conditions, eg refluxing triglyae or 
in sealed tube reactions, eixtures of products were obtained but by NMR 
none were found to contain both phosphorus and fluorine. These
observations contradict those of Burton and Flynn (1977), although it 
was found that heating triethyl phosphite with dibroaodifluoromethane in 
a sealed tube, followed by distillation under vacuua yielded diethyl 
broeodifluoroaethylphosphonate in low yield (Fig. 2.2.1(23)).
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Bromodifluoromethyl dialkyl phosphonates are known to react with 
activated zinc dust to for* dialkoxyphosphinyl difluoromethylzinc 
bromides (Burton, et al, 1982). When diethyl bromodifluoromethylphos- 
phonate was treated with a slight nolar excess of activated zinc dust 
(prepared as described by Rieke, et al, 1981) in anhydrous triglyme the 
majority of the zinc dust dissolved to leave a colourless solution of 
diethoxyphosphinyl difluoromethylzinc bromide (Fig. 2.2.1 (24)). 
Treatment of this solution with diethyl phosphorochloridate did not 
result in any coupling to form tetraethyl difluoromethylene- 
bisphosphonate. The analagous reaction with acetyl chloride is reported 
to give a good yield of diethyl 2-oxo-l,1-difluoropropylphosphonate 
(Fig. 2.2.1(25)) (Burton, et al. 1982a).
In view of these difficulties and the report that dibromo- 
difluoromethane would react directly with the sodium salt of diethyl 
phosphite (Burton and Flynn, 1980) the reaction with the sodium salt of 
diisopropyl phosphite was investigated. Reaction of dibromo- 
difluoromethane with two equivalents of sodium diisopropyl phosphite in 
hexane at low temperature followed by flash chromatography on silica gel 
yielded tetraisopropyl difluoromethylenebisphosphonate in 40% yield. 
This is comparable to the yields obtained for the tetraethyl and 
tetrabutyl esters synthesised by the two step route described earlier 
(Burton and Flynn, 1980). The reaction showed a surprising solvent 
effect in that if petroleum ether were used as the solvent the yield of 
product was greatly reduced (11% by a,P NMR).
2.2.2 Tetraisopropyl Monofluoromethylenebisphosphonate
The synthetic approach adopted was to synthesise tetraisopropyl 
bromofluoromethylenebisphosphonate and debrominate via positive halogen 
abstraction as described earlier (Seyferth and Harmor, 1973).
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p(EtO)3 P  ♦ CF2Br2 (EtO)2P— CF2Br EtBr
Fig. 2.2.1 Hie preparation and reactions of diethoocyphosphinyl 
difluoraBethylzinc bronide
2.2.2.1 Diisopropyl Dibronof luoromethylphosphonate
In contrast to the Arbuzov reaction of dibromodifluoromethane 
treatment of fluorotribronomethane with triisopropyl phosphite in 
refluxing diethyl ether yielded the desired product diisopropyl 
dibromofluoromethylphosphonate in good yield (Fig. 2.2.2.1). The
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corresponding reaction with the nuch cheaper Freon 
fluorotrichloronethane was investigated and was found not to occur in 
diethyl ether. In a sealed tube reaction between triisopropyl phosphite 
and f luorotrichloromethane a snail qualtity (J55%) of diisopropyl 
dichlorofluoronethylphosphonate was detectable by **P NMR spectroscopy. 
The lower reactivity of fluorotrichloromethane relative to fluorotri- 
bromomethane is not unexpected. In a recent report (Blackburn and 
Taylor, 1988) the reaction of fluorotrichloronethane with triethyl 
phosphite is found to require very forcing conditions.
(Pr'OljP .  CFBt3 (Prb)2P— CFBr2 ♦ Pr'Br
Fig. 2.2.2.1 The reaction of triisopropyl phosphite with fluorotribro-
nanethane
2.2.2.2 Hichaelis-Becker Reactions of Diisopropyl Dibronofluoronethyl­
phosphonate
Treatnent of diisopropyl dibronofluoromethylphosphonate with one 
nolar equivalent of sodiun diisopropyl phosphite in dry hexane at low 
tenperature did not yield any of the desired tetraisopropyl
bronofluoromethylenebisphosphonate. A nixture of products was obtained 
including tetraisopropyl nonofluoromethylenebisphosphonate. It appeared 
that nucleophilic debronination had occurred in situ. After
o o o o
IPr'O),
ÍPr'0)2
IPr'0)2
(HO)2f
Fig. 2.2.2.
Il H II II
,P— CFBr2 * (Pr'O^P-Ma* —  (Pr'O^P— CFBr — P(OPr')2
P— CHF— P(OPr')2
1) TMSBr
2) H20
I fi
3— CHF----P(OH)2
2) Work up 
O O
(Pr'0)2P — O---- P(OPr')2
1) TMSBr
2) H20
(HO)2P-----O — p io h )2
2(a) The synthesis of monofluoranpthylenrfjisphosphonic acid 
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optimisation of the reaction conditions the highest yield of 
tetraisopropyl monofluoromethylenebisphosphonate was obtained using 
three equivalents of sodium diisopropyl phosphite.
After flash chromatography of the crude reaction products on 
silica gel a fraction was obtained which contained tetraisopropyl 
monofluoromethylenebisphosphonate (65%) and tetraisopropyl pyrophosphate 
(35%) by 31P NMR spectroscopy. Tetraisopropyl pyrophosphate was 
identified by synthesis of an authentic sample (Steinberg, 1950). These 
two materials co-chromatographed on silica gel, however de­
esterification of the mixture with bromotrimethylsilane followed by 
anion exchange chromatography on DE52 cellulose gave bis(triethyl- 
ammonium) monofluoromethylenebisphosphonic acid. Further cation 
exchange chromatography on Dowex 50 resin yielded the free acid (Fig. 
2 . 2 . 2 . 2 ( a ) ) .
The first step of the reaction sequence is the debromination of 
diisopropyl dibromofluoromethylphosphonate by the phosphite anion. This 
process is anolagous to that described by Burton and Flynn (1980) for 
the treatment of diethyl bromodifluoromethylphosphonate with sodium 
diethyl phosphite (Fig. 2.2.2.2(b)). In the crude reaction mixture 
small quantities of diisopropyl broraofluoromethylphosphonate (8% by 31P 
MMR) were detected, having arisen from protonation of the anion.
The second step in the sequence is the reaction of the diisopropyl 
bromofluoromethylphosphonate anion with diisopropyl phosphorobromidate 
to yield tetraisopropyl bromofluoromethylenebisphosphonate. The 
isolation of tetraisopropyl fluoromethylenebisphosphonate can be 
ascribed to the ready nucleophilic debromination by the diisopropyl 
phosphite anion. This yields the sodium salt of tetraisopropyl 
monofluoromethylenebisphosphonate which would be expected to be very 
stable (the sodium salt of tetraisopropyl methylenebisphosphonate is a 
stable solid (Quimby, et aJ, 1968) (Fig. 2.2.2.2(c)).
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This was confirmed by the synthesis of an authentic sample of 
tetraisopropyl bromofluoromethylenebisphosphonate via the bromination
procedure of Quimby (1968) and treatment with the sodium salt of
diisopropyl phosphite in hexane at low temperature. The crude reaction 
products consisted of tetraisopropyl monofluoromethylenebisphosphonate 
(62%) and tetraisopropyl pyrophosphate (31%) by 31P NMR (Fig. 
2.2.2.2(c)), indicating that nucleophilic debromination does occur under 
the reaction conditions.
The formation of tetraisopropyl pyrophosphate as a by-product in 
Hichaelis-Becker reactions of both diisopropyl dibromofluoromethyl- 
phosphonate and tetraisopropyl bromofluoromethylenebisphosphonate was 
unexpected. This appears to arise from the reaction of sodium
o o 0
II II II
(Pr'0)2P-CFB r2 .  (P r'O y,P- Na* ——(Pr‘0)2P—CFBr + (PrO^P— Br
U-.*
0 0
II II
(EtO)2P—  CF2Br*(EtO)2P - Na* — (EtO^P— CF2 Na* ♦  (EtO^P-Br 
0
II
Fig. 2.2.2.2(b) Debrcninaticn of bronodifluotxaethyl- and dibrcno-
f lu o r c o e th y lp h o s p h c n a te s
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0
0
(Pr'0)2P------CFBr — P( OPr«>2
II
0
II
(Pr'O^P— CF—  P(OPr')2
Na*
0
7 '2
Fig. 2.2.2.2(c) Debrcraination of tetraisopropyl branofluoranethylene- 
bisphasphonate
diisopropyl phosphite with diisopropyl phosphorobromidate. This process 
is akin to that described by earlier authors (Steinberg, 1950; Atherton 
and Todd, 1947) for the base catalysed reaction of dialkyl phosphites 
with carbon tetrachloride.
It has been known since 1930 that the reaction between the sodium 
salt of diethyl phosphite and diethyl phosphorochloridate yielded 
tetraethyl pyrophosphate (Nylen, 1930); a close mimic of the observed 
reaction. Finally when the sodium salt of diisopropyl phosphite in 
hexane at low temperature was treated with an authentic sample of 
diisopropyl phosphorobromidate (Goldwhite and Saunders, 1955) a mixture 
of products were obtained including tetraisopropyl pyrophosphate (40% by 
31 P NMR).
It has recently been reported that tetraethyl monofluoromethylene- 
bisphosphonate can be synthesised from diethyl dichlorofluoromethyl- 
phosphonate and sodium diethyl phosphite (Blackburn and Taylor, 1988) 
(Fig. 2.2.2.2(d)). The mechanism is reported to be exactly analogous to 
that above.
A question arises as to the source of the bridge proton. In the 
Blackburn synthesis the final product is the sodium salt of tetraethyl 
monofluoromethylenebisphosphonate which is quenched on work up. However 
in the preparation from diisopropyl dibromofluoromethylphosphonate 
quenching the reaction with D*0 did not yield any deuterium 
incorporation in the product, indicating no carbanions present at the 
end of the reaction.
It was reported recently that on forming the sodium salt of 
dimethyl phosphite the initially formed anion was quantitatively 
alkylated by the remaining neutral ester; on quenching with D2O no 
phosphorus-centred anion was found to be present (Spears, et al, 1987)
Fig. 2.2.2.2(d) The synthesis of tetraethyl monofluorcBethylenebisphosphonate 
(Blackburn and Taylor, 1988)
(Fig. 2.2.2.2(e)). Repeating the experiment with diisopropyl phosphite 
in hexane it was found that on quenching with DxO only 50% of the 
diisopropyl phosphite had been converted into its carbanion (Fig.
0
0
II
Na* -P(OEt),
0
II
2
II
(EtO)2P— CF— P(0Et)2 
Na-
0
fl
(EtO)2P- :h f — p(OEt).
2
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2.2.2.2(e)). The reaainder had been alkylated to yield diisopropyl 
isopropylphosphonate. It is possible that the proton a  to the 
phosphorus atoa in this phosphonate is the source of the bridge proton 
in the final product. This side reaction is reported to be limited to 
the use of sodium hydride as the base in THF (Spears, et al. 1987); 
quantitative for the aethyl ester, ' less important for the ethyl ester, 
but froa the result above it is clear that with sodiua aetal used 
directly it also occurs to a significant extent with the isopropyl 
ester.
0 0
II Na II(R0)2P— H (RO LP - Na* ♦  H2
Na* |
OR OR
Fig. 2.2.2.2(e) A side reaction involved in forming the carbanicns of dialkyl 
phosphites
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Table 2.2.3 Hidiaelis-Becker reactions leading to fluorinated methylene- 
bisphosphonates
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2.2.3 Hichaelis-Becker Reactions of Other Fluorohalomethanes
In view of the results obtained above attempts were made to 
synthesise tetraisopropyl raonofluoromethylenebisphosphonate directly 
from fluorohalomethanes. The reactions of fluorotribromomethane, 
fluorotrichloromethane and fluorodibromomethane with sodium diisopropyl 
phosphite in hexane at low temperature were all investigated (Table 
2.2.3). Fluorodibromomethane gave the best yield (50% by 3,P NMR) but a 
complex mixture of products. Fluorotribromomethane gave a very complex 
product mixture with a low yield (22% by 3,P NMR) of tetraisopropyl 
monofluoromethylenebisphosphonate and the reaction of fluorotrichloro­
methane was only slightly better with a 30% yield (by 3IP NMR) of the 
desired product. These reactions were considered to hold no advantage 
over the above two step synthesis because of the increased difficulty in 
purifying the product.
The reaction of the sodium salt of diisopropyl phosphite with 
fluorotrichloromethane contrasts with that of the sodium salt of diethyl 
phosphite (Blackburn, et al, 1986). The differences appear to be 
related to the stability of the intermediate chlorofluoromethane- 
phosphonate carbanion. This is unstable at 0°C (Blackburn, et al, 
1985), but at -78°C the diisopropyl chlorofluoromethanephosphonate 
carbanion persists long enough to be phosphorylated to yield 
tetraisopropyl chlorofluoromethylenebisphosphonate.
2.3 Hydrolysis of Hetliylenebispllosplioiutss
Conversion of methylenebisphosphonic acid tetraesters to the 
corresponding free acids can be effected with concentrated hydrochloric 
acid at high temperature (Kosolapoff, 1950) but this often results in 
low yields. The need for these harsh conditions had led to the 
development of a range of trialkylhalogenosilanes for the 
transesterification of phosphate and phosphonate esters.
4 3
Iodotrimethylsilane has been reported to be very effective for the 
dealkylation of phosphate and phosphonate esters (Blackburn, 1980). The 
reaction involves extremely mild conditions and has been used to 
dealkylate the normally very reactive dialkyl phosphorobromidates 
(Chojnowski, et al, 1978). Bromotrimethylsilane gives virtually 
quantitative yields of the corresponding trimethylsilyl esters when 
reacted with phosphate esters at room temperature (Lalinde, et al, 
1983). This reagent is reported to give a cleaner reaction than 
iodotrimethylsilane (Hutchinson and Semple, 1985) which has to be used 
in the dark at low temperature. Bromotrimethylsilane was the reagent of 
choice for all deesterifications performed in this study (Fig. 2.3).
Methylenebisphosphonic acids produced by reaction with 
bromotrimethylsilane and hydrolysis were obtained as viscous oils and 
were usually converted into their tris(cyclohexylammonium) salts. This 
procedure was widely used in this study and the deesterification of 
tetraisopropyl difluoromethylenebisphosphonate (Section 2.5.7) may be 
considered typical.
2.4 Conclusions
Michaelis-Becker reactions of the appropriate fluorobromomethane 
may be used to synthesise fluorinated methylenebisphosphonates directly 
or they can be prepared by reaction of a precursor fluorobromomethyl- 
phosphonate. In the case of tetraisopropyl difluoromethylene­
bisphosphonate the first approach is the method of choice but for 
tetraisopropyl monofluoromethylenebisphosphonate the second approach is 
preferred as the yield is higher and the reaction mixture less complex. 
Both these methods appear more suited to the syntheses than 
fluorination of tetraalkyl methylenebisphosphonates.
44
0 0 0
Fig.
2.5
2.5.
RO----
0
II
CXY-----P — OR -
I I
OR OR
Me3SiBr
• Me SiO— P— CXY— P — OSiMe,
3 I I 3
Me^SiO OSiMe^
"TRIS
NH,
o
CYCLOHEXYL AMINE
SALT "  •
METHANOL
HO— P CXY----P — OH
I I
HO OH
2.3 Hie dealkylation of methylenebisptasphonates with brcrotrimethylsilane
Materials and Methods 
Materials
i) Starting materials were either commercially available or 
synthesised as described in the text. [3H]-UTP was obtained 
from Amersham (Amersham International PLC, Amersham, 
Buckinghamshire, U.K.).
ii) All solvents were dried and distilled before use.
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2.5.2 General Chemical Procedures
i) 1H NMR spectra were recorded at 220 MHz on a Perkin-Elner R34 
spectrometer or at 400 MHz on a Bruker WH400 spectrometer, with either 
tetramethylsilane (TMS) or sodium 3-(trimethylsilyl)-l-propane 
sulphonate (TSS) as internal standards. 3IP NMR spectra were recorded 
at 36.43 MHz on a Bruker WH90 spectrometer or at 162.0 MHz on a Bruker 
VH400 spectrometer. 3IP NMR shifts are quoted relative to an external 
standard of 85% H3PO4 with shifts to higher frequency expressed as 
positive.
1*F NMR spectra were recorded at 84.67 MHz or at 75.69 MHz on 
Bruker VH90 and Bruker VP80 spectrometers respectively. Where 
appropriate hexafluorobenzene, 1,2-difluorotetrachloroethane, fluoro- 
trichloromethane and trifluoroacetic acid were used as internal 
standards with shifts to increasing frequency given a positive sign. 
All 1*F NMR shifts are quoted relative to fluorotrichloromethane (CFCls, 
6 = 0  p.p.m.). 13C NMR spectra were recorded at 100.62 MHz on a Bruker
WH400 spectrometer or at 22.63 MHz on a Bruker WP80 spectrometer with 
TMS as an external reference.
ii) Mass spectra were recorded using a Kratos MS80 instrument fitted 
with a DS55 data system. Electron impact (El) spectra were recorded at 
70eV and for chemical ionisation (Cl) spectra ammonia was used as the 
reagent gas (Cload and Hutchinson, 1983a).
iii) Microanalyses were carried out by Butterworth Laboratories Ltd., 
Teddington, Middlesex, U.K.
iv) Compounds were usually purified by flash chromatography on silica 
gel (Still, et al. 1978).
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In listing NMR data the following abbreviations are used:v)
s singlet
d doublet
t triplet
q quartet
quint quintet
m multiplet
M series of multiplets
2.6 Experimental
Full NMR data for the fluorinated phosphonates and
bisphosphonates synthesised are listed in table 2.6(a). NMR data for 
the bisphosphonic acids synthesised are listed in table 2.6(b).
2.6.1 Preparation of Diethyl Bromodifluoromethylphosphonate
A mixture of dibromodifluoromethane (5.9cm3, 64 mmol) and triethyl 
phosphite (10.4cm3,60 mmol) was heated in a sealed glass tube for 24h at 
100°C . The crude product was distilled under vacuum to yield the title 
compound (90-92°C/10mmHg) as a colourless oil (3.0g, 19%). [Mass
spectrum (NHaCI) (M+H)* 266,268].
2.6.2 Preparation of Diisopropyl Dibromofluoromethylphosphonate
This was prepared from triisopropyl phosphite and fluorotribromo- 
methane essentially as described (Burton and Flynn, 1977). Purification 
by flash chromatography, elution with acetone/petroleum ether (1:20*/v), 
yielded the title compound as a colourless oil (19.4g, 78%). [Analysis 
C, 24.10; H, 4.12; P, 8.55; F, 4.86%. Ct Hi «BnF0:,P requires C.23.62; H, 
3.96; P, 8.70; F, 5.34%; Mass spectrum (NHsCI) (M ♦ H)* 355,357,359].
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2.6.3 Preparation of Tetraisopropyl Difluoromethylenebisphosphonate
A solution in dry hexane (10cm3) under nitrogen of sodium 
diisopropyl phosphite was prepared from diisopropyl phosphite ( 8.0g, 48 
mmol) and sodium metal (1.25g, 54 mmol). After cooling to -78#C a
solution of dibromodifluoromethane (2.20cm3, 24 mmol) in dry hexane 
(10cm3) was added dropwise over.30 min. The solution was stirred for 3h 
at -78°C and was then filtered through a plug of celite. Evaporation of 
the filtrate yielded a colourless oil which was distilled under vacuum. 
The fraction distilling in the range 75-85#C/0.8 mmHg was collected. 
Flash chro- matography on silica gel, elution with acetone/petroleum 
ether bpt 40-60°C (1:15*/v) yielded the title compound as a colourless 
oil (3.66g, 40%). [Analysis C, 40.15; H, 7.51; P, 16.25; F. 7.95%. 
CjaHisFiOsP* requires C, 41.06; H, 7.42; P, 16.29; F, 9.99%; Mass 
spectrum (NHaCI) (M + H)* 381.1427 (CisHiiFaOsPz calc. 381.1425)].
2.6.4 Preparation of Tetraisopropyl Bromofluoromethvlenebisphosphonate 
This was prepared by reaction of a mixture of tetraisopropyl 
monofluoromethylenebisphosphonate and tetraisopropyl pyrophosphate 
(l.Og, 1:1 by 3,P NMR, obtained during the preparation of tetraisopropyl 
monofluoromethylenebisphosphonic acid) with bromine essentially as 
described (Quimby, et al, 1968). Flash chromatography on silica gel, 
elution with acetone/petroleum ether (1:5 */»), yielded the title 
compound as a colourless oil (0.55g, 90%). [Analysis C, 35.12; H, 6.42; 
P, 14.20; F, 3.98%. CnHi.BrFCkPi requires C, 35.39; H, 6.40; P, 14.04; 
F, 4.31%; Mass spectrum (NHjCI) (M + H)* 441,443].
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Table 2.6(a) I*1R shifts of fluor mated phosphonates and bisphosphonates
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2.6.5 Preparation of Tetraisopropyl Pyrophosphate
This was prepared exactly as described (Steinberg, 1950) to yield 
the title compound, distilling at 101-102*C/0.1 mmHg (lit 94-99°C/0.01-
0.02 mmHg) , as a colourless oil (11.lg, 71%). [•H NMR (CDClj) 8 1.38
(24H, d. J=6.2Hz), 4.80 (4H,m) p.p.m.; 3*P NMR (CDCla) 6 -15.1
p . p . m . (s); l3C NMR (CDCla) 5 -23.4 (q, J«2.9 Hz), 73.9 (t, J=2.9Hz)
p.p.m.; Analysis C, 41.92; H, 8.34; P, 16.88%. Ci2H28O7P2 requires C,
41.62; H, 8.15; P, 17.89%; Mass spectrum (NHjCI) (N + H)* 347].
2.6.6 Preparation of Monofluoronethylenebisphosphonic Acid
To a solution in dry hexane (15cn3) of sodium diisopropyl 
phosphite (prepared from diisopropyl phosphite (1.50cm3 , 9nmol) and 
sodium (0.27g, 12 mmol) stirred at -78#C under nitrogen was added a 
solution in dry hexane (5cm3) of diisopropyl dibromof luoromethyl- 
phosphonate (1.07g, 3.0 mmol). After stirring at -78°C for 2h the 
solution was allowed to warm to room temperature; hexane (20cm3) was 
added and the solution filtered through celite. The filtrate was 
stripped in vacuo to yield a colourless oil.
Flash chromatography on silica gel, eluting with acetone/petroleum 
either (l:10w/v), gave a major fraction which contained tetraisopropyl 
monofluoromethylenebisphosphonate (65%) and tetraisopropyl pyrophosphate 
(35%) by 31P NMR. This fraction was treated with bromotrimethylsilane 
(6.0cm3, 45 mmol) for 48h, lyophilised, shaken with water (10cm3) and 
again lyophilised to yield a colourless oil.
Anion exchange chromatography on a DE52 cellulose column (3 x 33 
cm, HCOs* fora) with elution by a 0.1-0.5H linear gradient of tri- 
ethylaamonium bicarbonate (pH 7.5) yielded, after freeze drying, 
bis(triethylammonium) monofluoromethylenebisphosphonate as a white 
solid. Acid containing aliquots were detected by spotting onto 
chromatography paper and spraying with a phosphate detecting spray 
(Bockner, et al, 1981). Further ion exchange chromatography on a short
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column of Dowex 50 (H* form) yielded the title compound as a colourless 
oil (0.25g, 42%). [Analysis C, 6.17; H, 2.76; P, 30.67%. CHsFO.Pi 
requires C, 6.19; H, 2.58; P, 31.93%].
2.6.7 Preparation of Tris(cyclohexylammonium) Pitluoromethvlene-
Tetraisopropyl difluoromethylenebisphosphonate (0.50g, 1.3 mmol) 
was treated with bromotrimethylsilane (1.72cm3 , 13 mmol) under nitrogen 
for 48h. The product was lyophilised, shaken with water (10 cm3) and 
again lyophilised to yield a colourless oil. Treatment with methanol 
(5cm3) and cyclohexylamine (excess) yielded the crude title compound. 
Recrystallisation from methanol/diethyl ether yielded the title compound 
as a white crystalline solid (0.44g, 66%). [Analysis C, 44.76; H, 8.46; 
N, 7.97; F, 6.88%. C n H 43FiH3O.P1 requires C, 44.79; H, 8.51; N, 8.25; 
F, 7.46%].
2.6.8 Preparation of Tris(cyclohexylammonium) Bromofluoromethylene­
bisphosphonate
This was prepared from tetraisopropyl bromofluoromethylene 
bisphosphonate (0.25g, 0.57mmol) in a manner analagous to that above. 
Recrystallisation from methanol/diethyl ether yielded the title compound 
as a white solid <0.24g, 73%). [Analysis C, 39.99; H, 7.54; N, 7.24; 
F, 2.97; P, 10.36%. C1.H43BrFN3O.P3 requires C, 40.01; H, 7.60; N, 
7.37; F, 3.33; P, 10.86%].
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CHAPTER 3
MICHAEL REACTIONS OF TETRAALKYL ETHENYLIDENEBISPHOSPHONATES
3.1 Introduction
Alkylated methylenebisphosphonates are of interest as potential 
antiviral agents as modification of the alkyl substituent might enable 
bisphosphonates to be developed which were more readily taken up by 
cells and less readily absorbed by bones. Alkylated methylene­
bisphosphonates may be synthesised by reaction of the sodium, lithium or 
thallium(I) salts of methylenebisphosphonates (Quimby, et al, 1968; 
Seyferth and Marmor, 1973; Hutchinson and Semple, 1985) with alkyl 
iodides. However these methods do not readily lend themselves to the 
preparation of tetraalkyl methylenebisphosphonates with labile groups 
attached either to the bridge carbon atom or to the alkyl substituent.
The possibility exists however to synthesise novel substituted 
methylenebisphosphonates via reactions of the double bonds in
tetraalkyl alkylidenebisphosphonates. These may be synthesised by the 
Knoevenagel condensation of tetraalkyl methylenebisphosphonates with 
aldehydes and ketones (Lehnert, 1974). The parent compounds, tetraalkyl 
ethenylidenebisphosphonates, may be synthesised via the thermal 
dehydration of tetrasodium 1-hydroxyethylidenebisphosphonate (Carroll, 
1972) followed by treatment with triethylorthoformate (Nicholson, et 
al, 1970). A much improved preparation has recently been reported 
(Degenhardt and Burdsall, 1986) which involves the base catalysed 
condensation of tetraalkyl methylenebisphosphonate with formaldehyde 
(Fig. 3.1).
Although the conjugate addition of nucleophiles to a  , ß- unsatur­
ated carbonyl compounds is well documented (eg Bergmann, et al, 1959) ,
little has been reported on the analogous reaction with a, ß -  
unsaturated phosphonates. Diethyl ethenylphosphonate (Kosolapoff, 1948)
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is known to undergo a Michael-type reaction with organocuprate reagents 
(Nicotra, et al, 1984) and l-(functionally) substituted vinyl- 
phosphonates have been reported to undero Michael additions with various 
organonetallic reagents (Barbot, et al, 1984), but no analogous 
reaction with tetraethyl ethenylidenebisphosphonate has been described.
<0R)2 MeOH
TsOH
Fig. 3.1 Syntheses of tetraalkyl ethenylidenebisphosphcrates
In this study the Michael-type reactions of tetraalkyl 
ethenylidenebisphosphonates were investigated with a view to increasing
the range of substituted methylenebisphosphonates which could be assayed 
against the RNA polymerase of influenza.
3.2 Results and Discussion
When tetraethyl or tetraisopropyl ethenylidenebisphosphonate was 
treated with diethylamine in chloroform a Michael-type addition was 
observed across the carbon-carbon double bond. Similar additions were 
observed with other amines, thiols and also dialkyl phosphites when the 
reaction was catalysed by base (diisopropylamine or 2,2,6,6-tetramethyl- 
piperidine) (Table 3.2(a)). The reactions presumably proceed via 
formation of an intermediate zwitterion with the negative charge on the 
bridge carbon atom stabilised by the two phosphorus atoms; 
intramolecular proton transfer yielding the reaction product (Fig. 
3.2(a)). On a small scale (50-100 mg) the reactions were observed to be 
quantitative by 1 H and 3 *P NMR spectroscopy.
Diethyl and diisopropyl phosphite took part in the reaction only 
when diisopropylamine or 2,2,6,6-tetramethylpiperidine was added as a 
catalyst. In these reactions only carbon-phosphorus bond formation was 
observed. There was no evidence (by 31P NMR spectroscopy) for carbon- 
oxygen bond formation.
Oxygen nucleophiles did not take part in the reaction. Treatment 
of tetraethyl ethenylidenebisphosphonate with water, methanol, phenol 
or acetic acid did not result in any reaction over 72h. More potent 
nucleophiles such as ethoxide or hydroxide ions led to hydrolysis of the 
bisphosphonate before any Michael addition was observed.
Carbon nucleophiles did not give a Michael reaction. 
Tetraisopropyl and tetraethyl nethylenebisphosphonates (both in the 
presence and absence of added diisopropylamine) failed to react in 72h. 
Addition of butyllithium or methyllithium at low temperature yielded a 
complex mixture of products none of which had the characteristics of a 
Michael adduct.
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Fig. 3.2(a) The Michael addition of diethylamine to tetraethyl ethenylidene- 
bisphosphonate
When the Michael reactions were carried out on a larger scale (2g) 
the products were still obtained in high yield. For example treatment 
of tetraethyl ethenylidenebisphosphonate with a slight molar excess of 
thiophenol for 24h at 45°C yielded C-(thiophenyl)methyl methylene- 
bisphosphonate as the dominant product (97%) by 31P NMR (Table 3.2(b)).
The Michael reaction is, in principle, reversible (March, 1977) 
and in the adducts it was found that when X was a good leaving group (X- 
H having undergone reaction to yield the adduct) the adduct was unstable 
to elimination. Only the products formed from reactions of thiols were 
stable enough to be isolated and transesterified with 
bromotrimethylsilane. For example flash chromatography of crude
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Table 3.2(a) Reactions of tetraalkyl ethenylidenebisphosphcnates with nucleophile
REACTANTd Reaction
time
(min)
* 4  NMD* 
of adduct 
(ppjn)
NHjCI
IM*H)*
TETRAETHYL ESTER 
Nitrogen nucleophiles
EtjNH < 5 238 374
o <  5 22-4 388
C M
< 5 1*6 369
O nh2 < S 229 400
© - NM2 12 h 220 394
HjNCH^CHjNhJ <  5 226 661
- - -
PH2NHe - - -
Sulphur nucleophiles
© - S H 60 212 411
hoch2ch2sh 720 217 379
EtSH 60 216 363
PrSH 70 2T7 377
W H 150 217 504
Phosphorus nucleophiles 
0
(EtO) P—He 
0 2
- - -
(EtO)2P-H ♦  Pr^ Ntf 180 2*0 ld.J«269) 439
0 287 11. J *26-9)
(Pr'O^P-H6 - - -
(PHO^P—H*Pr^ NHC 36h 25-9(dd,J=30,
J=24).22-3(d,
J«24).22-3ld.
J=30)
467
TE TR A ISOPROPYL ESTER 
Nitrogen nucleophiles
EtjNH <  S 21-2 430
o < 5 205 444
> T nHw < 5 175 42S
O m 2
< S 209 457
17h 200 450
Sulphur nucleophiles
<©-SH 240 102 468
HOCH2CH2SH 40h 197 435
a) In COCl^  b) Reaction at both -NH^groups c) One equivalent 
d) Reaction in COCI^ as described e) No reaction
Table 3.2(b) Preparative scale Michael reactions of tetraethyl ethenylidene-
bispho6phonate
REACTANT Temperature
C O
Starting 
Material3 {%)
Michael
Adduct3 (%)
EtjNH 20 3 94
O - S H 45 2 97(91)b
C12H2SSH
45 3 97(92f
0
II
(EtO)2P-H
45 3 92
a) By^1P NMR spectroscopy
b) Isolated yield
C- (diethylaaino)aethyl nethylenebisphosphonate on silica gel and 
evaporation of the eluate fractions gave an almost quantitative yield of 
tetraethyl ethenylidenebisphosphonate. Elimination of diethylamine had 
occurred.
Differences in the stabilities of the Michael adducts could 
readily be demonstrated by 'H NMR spectroscopy. Dissolving C- 
(thiophenyl)methyl methylenebisphosphonate in d<-methanol resulted in no 
change in the 1H NMR spectrum over 24h. On the other hand, dissolving 
C-(diethylamino)methyl methylenebisphosphonate in d<-methanol resulted 
in rapid deuterium exchange of the bridge proton and this was confirmed 
by mass spectrometric analysis of the residue after evaporation of the 
solvent (Fig. 3.2(b)).
O H O 0 H 0
(EtO^P-----C----- P(OEt»2
s^ O>
IEtO)2P-----C----- P[OEtl2
(EtOljP-----C ----- P(OEt)2
s^ O>
IEIOIj P-----C ----- P(OEtl2
CH— NEt2
Fig. 3.2(b) Deuteriim exchange on dissolving C-substituted methylene- 
bisphosphonates in methanol-di
Changing from a non-polar solvent (CHClt) to a polar protic 
solvent (NeOH) would be expected to increase the rate of Michael 
reaction via stabilisation of the zwitterionic intermediate and 
providing an additional proton source to neutralise the negative charge 
on the bridge carbon atom. This was found to be the case; in 
chloroform,aniline required 400 min for complete reaction at 45®C but 
under identical conditions in d«-methanol the reaction was complete in 
under 30 min (Table 3.2(c)).
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Table 3.2(c) Reaction of 4-substituted anilines with tetraethyl ethenylidene-
bispbospbanate
X-© " NH2 pKa(of conjugate 
acid)
SOLVENT Temperature
(°C)
Time for 
reaction
X= -OMe 5-3 cd3oo 45 <5min
X= -H 4*3 cd3oo 45 27min
X= -H 4-3 cd ci3 45 400min
X= -Br 38 cd3oo 45 220min
§1X 10 c d 3oo 45 90h
The Michael reaction of tetraethyl ethenylidenebisphosphonate with 
a series of 4-substituted anilines was investigated (Table 3.2(c)). It 
was observed that strongly basic anilines which had a high pK. for their 
conjugate acid (eg 4-methoxyaniline) reacted rapidly but less basic 
anilines reacted more slowly. The presence of a high electron density 
on the attacking nucleophile appears to be important in these reactions.
Tetraisopropyl ethenylidenebisphosphonate was found to undergo 
Michael additions more slowly (Table 3.2(a)) as would be expected on 
purely steric grounds. However on examination of the 13C NMR chemical 
shifts of methylenebisphosphonates and their anions it is found that 
the 1J *3c - 3 , P coupling constant is increased upon anion formation 
consistent with a change in hybridisation from sp3 to sp* (Strothers,
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1974) and that the chemical shift moves upfield (Semple, 1986) 
indicating negligible delocalisation of the negative charge (Gray, 
1973). Thus in foraing the intermediate zwitterion it appears that the 
phosphate ester groups may be moved slightly apart as the PCP bond angle 
increases upon change in hybridisation. This would relieve some of the 
steric crowding in tetraisopropyl ethenylidenebisphosphonate and might 
be expected to facilitate the reaction.
3.3 Conclusions
Tetraalkyl ethenylidenebisphosphonates can undergo a facile
Michael type reaction with soft nucleophiles to yield C-substituted 
methylenebisphosphonates. In the case of sulphur nucleophiles the 
products are stable and can be readily deesterified with
bromotrimethylsilane to yield C-substituted methylenebisphosphonic 
acids. The reaction is high yielding and with sulphur nucleophiles the 
products are readily isolated by flash chromatography on silica gel. 
This procedure is useful for the preparation of lipophilic methylene­
bisphosphonates as even dodecyl-l-thiol reacts to give a Michael adduct 
in high yield.
3.4 Experimental
3.4.1 Preparation of Tetraethyl Ethenylidenebisphosphonate
This was prepared as described (Degenhardt and Burdsall, 1986) and 
purified by distillation under vacuum at 120-121#C/0.2 mmHg (lit 115- 
116°C/0.05 mmHg) to yield the title compound as a colourless oil (13.6g, 
65%). I* H NMR (CDCla) 6 1.32 (12H. t, J-7.1 Hz), 4.12 (8H,m), 6.97 (2H. 
distorted dd, J=*33.8 Hz, J*37.8 Hz) p.p.m.; 3lP NMR (CDCla) 6 13.0(s) 
p.p.m.; *»C NMR (CDCla) 5 148.5 (s,broad), 131.5 (t,J-166.6Hz), 62.0
(t.*3*2.8 Hz), 15.7 (t,J= 3.3 Hz) p.p.m.; Analysis C, 39.98; H, 7.67%. 
CioH22O*P* requires C. 40.01; H, 7.39%; Mass spectrum (NHaCI) (M*H)‘ 
301.0970 (C10H2aO.P1 calc. 301.0970)].
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3.4.2 Preparation of Tetraisopropvl Ethenvlidenebisphosphonate
This was synthesised in an analogous manner to the tetraethyl 
ester described above except that in the first stage of the preparation 
the reaction mixture was heated for eleven days. Distillation under 
vacuum yielded the title compound (114-115°C/0.15 mmHg) as a colourless 
oil (13.5g, 33%). [«H NMR (CDCls) 8 1.35 (24H, dd, J=7.2Hz, J=6.1Hz),
4.75 (4H,m), 6.96 (2H, distorted dd, J=34.4Hz, J=38.3Hz) p.p.m.; 3«P 
NMR (CDCla) 8 11.3(a) p.p.m.; ‘3C NMR (CDCls) 8 147.2 (s), 134.7 
(t,J«169Hz), 71.2 (t,J=3.2Hz), 23.8 (dt, J=2.5 Hz, J»22 Hz) p.p.m.; 
Analysis C, 46.81; H, 8.62; P, 17.51%. CnHaoOePj requires C, 47.20; 
H, 8.49; P, 17.38%; Mass spectrum (NHsCI) (M+H)* 357.1637 (cnHsiOiP* 
calc. 357.1641)].
3.4.3 Michael Addition Reactions
3.4.3.1 NMR Scale Experiments
To tetraethyl ethenylidenebisphosphonate (75mg, 0.25 mmol) in
CDCls (0.25cm3) was added a solution of thiophenol (50 mg, 0.45 mmol) in 
CDCla (0.25 cm3). After rapid mixing the solution was maintained at 
45*C and the reaction followed by * H NMR spectroscopy. When no further 
change in the 'H NMR spectrum occurred the 31P NMR spectrum was 
recorded. The solvent was removed by blowing nitrogen through the 
solution and a mass spectrum recorded of the residue. For other Michael 
additions a similar procedure was employed except that when dialkyl 
phosphites were used as the nucleophiles one equivalent of
diisopropylamine was also added.
Tibie 3.4.3.2 í«R characteristics of tetraethyl C-(thioaUcyl)«ethyl
■etbylenebisptosphcnates
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Table 3.4.4 If® characteristics of tris(cyclohexylannoniun) C-(thioalkyl)nethyl
methylenebisphosphcnates
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3-4.3.2 Preparative Scale Reactions - Synthesis of Tetraethyl 
C-(Thioalkyl)»ethyl Hethylenebisphosphonates
To a solution of tetraethyl ethenylidenebisphosphonate (2.0g, 6.67 
mmol) in chloroform (15cm3) was added the alkylthiol (13.3 mmol) via 
syringe. After stirring at 40°C for 2h (after which time no starting 
material was detectable by TLC on silica gel) the solvent was stripped in 
vacuo to yield an oil. Flash chromatography on silica gel, elution with 
methanol/diethyl ether (l:20v/v) yielded the Michael adduct (2:90%). In 
the case of ethane-l-thiol 8 equivalents were added. Data for all C- 
(thioalkyl)methyl methylenebisphosphonates prepared via this route are 
listed in table 3.4.3.2.
3.4.4 Preparation of Tris(cyclohexvlammonium) C-(Thioalkvl)methyl
Methylenebisphosphonates
The bisphosphonate esters (0.5g) were deesterified with 
bromotrimethylsilane via the usual procedure (section 2.5.7). The crude 
salts were recrystallised from methanol-water (5:1)/diethyl ether to 
yield the title compounds as white solids (2:70%). Data for all 
compounds synthesised via this route are listed in table 3.4.4.
3.4.5 Preparation of Tris(cyclohexvlammonium) Ethenylidene­
bisphosphonate
Tetraethyl ethenylidenebisphosphonate (4.00g, 13.3 mmol) was
deesterified as described above. The crude product was recrystallised 
from methanol-water (10:1)/diethyl ether to yield the title compound as 
a white solid (4.23g, 67%). [' H NMR (D*0) 8 1.1-1.5<15H,m), 1.65 (3H,m), 
1.80 (6R,m), 2.0 (6H,m), 3.15 (3H,m), 6.22 (2H,dd,J=35.6Hz, J«33.3Hz)
p.p.m.; 3«P MMR (D*0) 8 11.7 (s) p.p.m.; (Analysis C, 49.37; H, 9.12;
N, 8.00; P, 11.90%. C*oH««N30*P2 requires C. 49.57; H, 9.15; N, 8.67;
P, 12.79%].
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3'4-6 Preparation of Ethenylidenebisphosphonic Acid
The above salt was passed down a short column (2 x 15cm) of Dowex 
50 (H* form) ion exchange resin, eluting with water. Lyophilisation of 
the eluate yielded the title compound as a hygroscopic white solid 
(1.52g, 92%). [«H NNR (D.0) 6 6.67 (2H. dd, J«35.6Hz, J«37.8Hz) p.p.«.; 
,,p NMR (Da0> 5 12.5(s) p.p.m.; *»C NMR (DaO) Ô 144.8(s), 136.7 (t,
J-161 Hz) p.p.m.; Analysis C, 12.59; H. 3.44%. C*H.O*P. requires C, 
12.78; H, 3.22%].
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CHAPTER 4
CYCLOPROPYL DERIVATIVES OF PYROPHOSPHATE ANALOGUES
4.1 Background
Previously the cyclopropyl derivatives of phosphonoacetic acid and 
methylenebisphosphonic acid have not been assayed for antiviral activity 
and no synthesis of cyclopropane-1,1-bisphosphonic acid exists in the 
literature. In cyclopropane itself (Jones and Stoicheff, 1964) the 
carbon-carbon bond lengths (0.1514nm) are reduced relative to propane 
(0.1526nm) (Lide, 1960) and the HCH bond angles are increased from 
107° to 116.5°. Analogous changes would be expected to occur on ring 
formation at the bridge carbon atom in methylenebisphosphonic acid and 
phosphonoacetic acid. For example the PCP bond angle in cyclopropane- 
1, 1-bisphosphonic acid (27) would be expected to be larger, and the 
carbon-phosphorus bond length shorter, than in methylenebisphosphonic 
acid. These changes might have significant effects on the ability of 
these compounds to chelate zinc. In this study 1-phosphonocyclopropane 
carboxylic acid (Fig. 4.1(26)) and cyclopropane-1,1-bisphosphonic acid 
(Fig. 4.1(27)) were synthesised and their activities against the RNA 
polymerase of influenza examined.
The synthesis of 1-phosphonocyclopropanecarboxylic acid has been 
described in the literature (Erion and Valsh, 1987) and the preparation 
of cyclopropane-1,1-bisphosphonic acid is discussed below.
4.2 Introduction - Cyclopropane-1,1-bisphosphonate
The recent improvement in the synthesis of tetraalkyl ethenylidene- 
bisphosphonates (Degenhardt and Burdsall, 1986) suggests the possibility 
of synthesising tetraalkyl cyclopropane-1,1-bisphosphonate; hence the 
corresponding bisphosphonic acid, via a classical Simmons-Smith reaction
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Fig. 4.1(26) 1-K>osphooocyclopropanecarbcixylic add
(27) Cyclopropane-1, 1-bisphasphcmc acid
(Simmons and Snith, 1959). This reaction has been modified by later 
authors e.g. use of diethylzinc (Furukawa, et al, 1968, 1969) and has 
enabled a wide range of cyclopropyl derivatives to be produced from 
carbon-carbon double bonds.
However these reactions proceed via an electrophilic attack on the 
double bond which in the case of tetraalkyl ethenylidenebisphosphonate 
is unlikely to be successful as the double bond in this compound is 
extremely polar and prefers to react with nucleophiles (Chapter 3). 
Tetraethyl ethenylidenebisphosphonate resisted epoxidation with MCPBA 
under forcing conditions or reaction with trifluoroperacetic acid which 
can form epoxides with electron poor double bonds (Emmons and Pagano, 
1955).
Grieco has described the construction of the cyclopropane unit via 
the reaction of alkylidene phosphoranes with a series of a  , (J- 
unsaturated esters (Grieco and Finkelhor, 1972). This reaction closely 
resembles the Michael reactions of tetraalkyl ethenylidine- 
bisphosphonates (Chapter 3) but is specific for the preparation of the 
gemdimethylcyclopropyl functionality (Fig. 4.2(a)).
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Fig. 4.2(a) The reaction of triphenylphosphonium isopropylide with 
a ,p -unsaturated esters
0 H Q O H O
II I II x c h 2c h 2y  jf y  jj
(RO)?P-- C —P(0R)2 - ----------------- -- (RO)2P— C— P(OR)2
CH2CH2Y
TIOEt
0 .. 0 0 0
II L . II II
2 /  '2 -------------- - ,r o ,2P P(OR)2
CHj CHjY c Hj - c h 2
Fig. 4.2(b) The synthetic approach adopted for the synthesis of tetraalkyl 
cyclopropane-1,1-bisphosphonate.
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An alternative approach to the synthesis of tetraalkyl 
cyclopropane-1,1-bisphosphonate is to prepare a suitable precursor which 
can by cyclised via an intramolecular reaction. The synthetic approach 
adopted is shown in Fig. 4.2(b)).
This synthesis requires the alkylation of tetraalkyl methylene- 
bisphosphonate; a process which has been known for some time. The 
monoalkylation of both the potassium (Kosolopoff, 1953) and sodium 
(Cotton and Schunn, 1963) salts of tetraethyl methylenebisphosphonate 
occurs in low yield. Alkylation of the sodium salt of tetraisopropyl 
methylenebisphonate gives a slightly improved yield (Quimby, et al, 
1968). In situ alkylation of the lithium salt of tetraethyl
chloromethylenebisphosphonate has also been reported (Seyferth and 
Marmor, 1973).
Later authors (Hutchinson and Semple, 1985) report poor yields of 
alkylation of tetraisopropyl methylene- and halagenomethylene- 
bisphosphonates when sodium, sodium hydride or butyllithium were used to 
form the reactive anions. Exclusive monoalkylation did not occur but 
dialkylation and cleavage reactions were found to interfere. Similar 
results were observed by Quimby et al (1968) (Fig. 4.2(c)).
In the same publication good yields of monoalkylation were 
observed when the thallium(I) salt of tetraisopropyl methylene- or 
halogenomethylenebisphosphonate was treated with excess of a primary 
alkyl iodide (Hutchinson and Semple, 1985) . The use of other alkyl 
halides results in much lower yields of alkylation. Similar results 
have been reported for the alkylation of P -diketones via thallium(I)
intermediates (Taylor, et al, 1968).
In view of these results 3-bis(diisopropylphosphono)-1-iodopropane 
was selected as a target molecule (Fig. 4.2(d)). In this study this 
compound was prepared and ring-closed via an intramolecular alkylation 
of the thallium(I) intermediate.
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Fia. 4.3.1 The synthesis of bis (cyclohexylanincmuni) 1 -phosphonocyclopropane- 
carbaxylate
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with 1,2-dibromoethane, sodium hydroxide and TEBA 
(triethylbenzylammonium chloride) yielded t-butyl diethyl 1- 
phosphonocyclopropanecarboxylate (Erion and Walsh, 1987; Fig. 4.3.1). 
A longer reaction tine than reported was used to totally remove any t- 
butyl diethyl phosphonoacetate that might remain at the end of the 
reaction as this was found to co-chromatograph with the desired product. 
The use of benzyltrimethylammonium chloride as a phase transfer catalyst 
was found not to be effective in the reaction, presumably due to less 
favourable solubility properties.
When the reaction was attempted with a commercially available 
alternative starting product; triethyl phosphonoacetate, no alkylation 
was detected but a rapid and total hydrolysis to diethyl phosphonoacetic 
acid was observed. The hydrolysis of triethyl phosphonoacetate is 
reported to be rapid when treated with 1M sodium hydroxide solution at 
room temperature (Clayton, et al, 1979). On reducing the concentration 
of sodium hydroxide to 5% total hydrolysis was still observed.
Hydrolysis of the t-butyl ester was readily accomplished by 
treatment with cold TFA (Erion and Walsh, 1987). Residual TFA was 
removed by washing a solution of the crude product in dichloromethane 
with brine. Drying and evaporation of the organic layer yielded 
diethyl 1-phosphonocarboxylic acid of sufficient purity to be used 
without further purification (Fig. 4.3.1).
Dealkylation of the phosphonate ester groups with 
bromotrimethylsilane via the usual procedure (section 2.5.7) did not 
yield 1-phosphonocyclopropanecarboxylic acid as the sole product. It 
was accompanied by 20% (by 1 H NMR) of products arising from opening 
of the cyclopropane ring. Purification of the bromotrimethylsilane had 
no significant effect on this. The title compound was obtained pure as 
its bis(cyclohexylammonium) salt by treatment of the crude acid with 
excess cyclohexylamine and fractional crystallisation. Thus the target 
molecule was prepared in an overall yield of 31% (4 steps).
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4.3.2 Synthesis of Cyclopropane-1,1-bisphosphonic Acid
Tetraisopropyl methylenebisphosphonate; synthesised as described 
(Roy, 1966), was readily converted into its thallium(I) salt by 
treatment with thallium(I) ethoxide (Hutchinson and Semple, 1985). 
However when reacted with excess 1,2-diiodoethane little alkylation (<5% 
by 31P NMR) was observed. The primary alkyl iodide was found to be very 
unstable under the reaction conditions. Thus 3-bis(diisopropyl-
phosphono)-1-iodopropane (Fig. 4.2(d)) could not be prepared via a 
direct alkylation with 1,2-diiodoethane. It was thus found necessary to 
prepare a primary alkyl iodide with a stable substituent at the 2- 
position that could be developed into an iodo-substituent after 
alkylation.
4.3.2.1 Synthesis of 3-Bis(diisopropylphosphono)propan-l-ol
Alkylation of the thallium(I) salt of tetraisopropyl methylene­
bisphosphonate with 6-iodohexyltetrahydropyranyl ether is known to occur 
in good yield (Semple, 1986), hence the analogous reaction with 2-
iodoethyltetrahydropyranyl ether was expected to be equally as facile as 
the reaction proceeds more readily with smaller alkyl iodides
(Hutchinson and Semple, 1985). After alkylation, removal of the ether
group by acid hydrolysis would yield an alcohol functionality which 
could readily be developed to a primary iodide.
The conversion of alcohols into their tetrahydropyranyl ethers is 
recognised as a good method of protecting thejp (Greene, 1981).
Treatment of 2-iodoethanol with excess dihydropyran in dichloromethane 
in the presence of PPTS (pyridinium p-toluene sulphonate, a mild acid 
catalyst; Hiyashita, et al, 1977) yielded, after vacuum distillation, 2- 
iodoethyltetrahydropyranyl ether in 94% yield (Fig. 4.3.2.1(a)).
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Treatment of the thalliun(I) salt of tetraisopropyl methylene- 
bisphosphonate with excess 2-iodoethyltetrahydropyranyl ether gave only 
a poor yield (24% by »‘P NMR) of alkylation. (Fig. 4.3.2.1(b)). Under 
identical conditions iodoethane yielded 75% (by 31P NNR) of mono­
alkylation and an isolated yield of 45% is reported (Hutchinson and
Fig. 4.3.2.1(a) The protection of 2-iodoethanol as its tetrahydropyranyl ether
Semple, 1985) for the reaction with iodoethane. Few cleavage products 
were detected but attack at phosphorus by the excess thallium(I) 
ethoxide; needed for complete formation of the salt, was observed.
The anion prepared from tetraisopropyl chloromethylene- 
bisphosphonate is more stable and usually gives higher yields of 
alkylation (Hutchinson and Semple, 1985). However with 2- 
iodoethyltetrahydropyranyl ether this was found not to be the case. 
Only 20% (by 31P NMR) of monoalkylation was observed and also some 
positive chlorine abstraction occurred yielding a more complex product 
mixture. These difficulties in alkylation can be rationalised by steric 
hindrance between the bulky nucleophile and the tetrahydropyranyl ring 
of the protected iodoalcohol (Fig. 4.3.2.3(b)). The tetrahydropyranyl 
ring and the iodine atom are probably in a trans orientation in the 
conformational ground state of the molecule. Alkylation of thallium(I) 
salts of tetraisopropyl methylenebisphosphonates is very dependent on 
steric effects; giving much reduced yields with secondary alkyl iodides 
(Hutchinson and Semple, 1985).
PPTS
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0 0 1) TIOEt 0
(Pr'O) P---- CH— P(OPr')2
2)ICH2CH2OTHP
c h 2ch2othp
/  PPTS 
EtOH
0 0
(Pr'0)2P— CH----P(OPr')2
II I I
CH2CH2OH
Fig. 4.3.2.1(b) The preparation of 3-bis(diisopropylphospbcno)propan-l-ol
The 3-bis (diisopropylphosphono) propyltetrahydropyranyl ether co­
chromatographed with tetraisopropyl methylenebisphosphonate. However 
after deprotection of the alcohol functionality with PPTS in ethanol 
(Miyashita, et al. 1977), the presence of the hydroxyl group caused a 
much greater affinity for silica gel, hence easy separation, to yield 
pure 3-bis(diisopropylphosphono)propan-l-ol as a colourless oil (Fig. 
4.3.2.1(b)).
4.3.2.2 Synthesis of 3-Bis(diisopropylohosphono)-l-iodonropane
The preparation of the title compound required conversion of the 
above alcohol (Fig. 4.3.2.1(b)) into the corresponding iodide. Primary 
alcohols iodinate readily with phosphorus and iodine (eg Streitwieser
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and Heathcock, 1981) but this procedure would cause reaction of the 
bridge proton to yield an unstable C-nlkyl iodomethylenebisphosphonate. 
More recently iodination of prinary and secondary hydroxyl groups has 
been reported to occur in good yield (Verheyden and Noffatt, 1970, 
1972). However the nethod chosen was the classical route via formation 
of an intermediate tosylate followed by displacement with iodide.
Treatment of 3-bis(diisopropylphosphono)propan-l-ol with p-toluene 
sulphonyl chloride in pyridine (as used by McMurry, st si. 1979) caused 
an almost quantitative reaction of the hydroxyl group. Flash chroma­
tography yielded 3-bis(diisopropylphosphono)propan-l-ol tosylate in 72% 
yield (Fig. 4.3.2.2).
0 0
CH2CH2OH
PYRIDINE C H j - 0 - S O j C I
ACETONE Nal
Fig. 4.3.2.2 Preparation of 3-bis (diisopropylphosphonoM-iodopropane
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A clean displacement of the tosyl group was effected by refluxing 
in acetone with excess sodium iodide. After flash chromatography the 
title compound was obtained as a colourless oil (Fig. 4.3.2.2).
4-3.2.3 Cylisation of 3-Bis(diisopropylphosphono)-1-iodopropane
Treatment of the title compound with one equivalent of thallium 
(I) ethoxide in THF at room temperature caused the formation of an 
instantaneous precipitate of thallium(I) iodide. A *«P NMR spectrum 
indicated >95% of tetraisopropyl cyclopropane-1,1-bisphosphonate to be 
present in the crude reaction mixture. Work up as described (section 
4.6.10) yielded the desired tetraisopropyl cyclopropane-1,1- 
bisphosphonate as a colourless oil in 70% yield (Fig. 4.3.2.3(a)).
Fig. 4.3.2.3(a) Cyclisation of 3-bis(diisopropylphosphono)-1-iodcprcpane
Alkylation of the thallium(I) salts of methylenebisphosphonates 
(Hutchinson and Semple, 1985) and of |3-dicarbonyl compounds (Taylor, 
et al, 1968) usually require reaction times of 4-24h. The above 
reaction is considerably faster than this as it is an intramolecular 
rather than an intermolecular reaction, hence there is a far greater 
probability of close proximity of the two reacting centers. The lowest 
energy rotational conformation about the Ci-C* bond in the title 
compound (Fig. 4.3.2.3(b)) probably places the bis(diisopropylphosphono)
0 B fi 0IIII TtOEt
THF
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methyl group and the iodine atom in a trans orientation. After 
deprotonation the carbanion centre is in an ideal position for attack on 
Ci which is required for displacement of the iodine atom as iodide.
Fig. 4.3.2.3(b) Intramolecular and intermolecular alkylations of the thallium(I) 
salts of methylenebisphosphonates
4.3.2.4 Dealkylation of Tetraisopropyl Cyclopropane-1,1- 
bisphosphonate
The cyclopropane ring was found to be very stable under the 
standard reaction conditions used for dealkylation (section 2.5.7). 
Upon treatment with bromotrimethylsilane and aqueous hydrolysis no ring 
opening or side reactions were detectable by * H NMF spectroscopy. 
Cyclopropane rings exhibit considerable ring strain (Liebman and 
Greenberg, 1987) and in particular rings activated by electron 
withdrawing groups readily undergo reactions with nucleophiles leading 
to ring opening (Danishefsky. 1978). This was found to be a problem
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during the dealkylation of diethyl 1-phosphonocyclopropanecarboxylic 
acid (section 4.3.2). Reactions of cyclopropanes can mimic alkenes 
(Meijere, 1979) and during the dealkylation of tetraethyl ethenylidene- 
bisphosphonate reactions of the double bond were observed. The stability 
of the cyclopropane ring under the reaction conditions used for 
dealkylation was thus unexpected. Cyclopropane-1,1-bisphosphonic acid 
was readily isolated as its tris(cyclohexylammonium) salt (Fig. 
4.3.2.4) .
(Pr'OljP— -C------PlOPr'Ij (HOljP— -C------P(0H>
/  \  1) TMSBr /  \
/  '  , , o  _ ' -  , /  \  TRIS
CH^— CH , 21 H2°  CH;--------CH„"2
BICYaOHEXYLAMINE2
Fig. 4.3.2.4 Preparation of tris(cyclohexylanroniun) cyclopropane-1,
1-bisphosphcnate
4.4 Preparation of Larger Ring Sizes
It was hoped that the route described above would be readily 
adaptable for the synthesis of cycloalkyl-1,1-bisphosphonates of other 
ring sizes. This requires the syntheses of the appropriate precursor 
iodoalcohols; whose preparation may be accomplished by cleavage of 
cyclic ethers with Lewis acids in the presence of iodide ion. 
Tetrahydrofuran may be cleaved to 4-iodobutan-l-ol upon treatment with 
boron trifluoride-etherate and sodium iodide (Mandai, et al, 1985). The 
same reaction may be accomplished with sodium borohydride and molecular 
iodine (Long and Freeguard, 1965) but these methods appear to be 
restricted to tetrahydrofuran (Semple, 1985). However the combination 
of diborane and iodine (Long and Freeguard, 1964) is applicable to a 
wide range of cyclic ethers (Semple, 1985).
Using this combination of reagents 4-iodobutan-l-ol was readily 
prepared from tetrahydrofuran but protection of the alcohol group as its 
tetrahydropyranyl ether was impossible. The 4-iodobutan-l-ol rapidly 
cyclised to yield tetrahydrofuran even in the dark at -20°C. It was 
considered that this would be a problem for iodoalcohols containing 
three or more carbon atoms. • Thus for larger rings it is necessary to 
include the iodide functionality after the protection of the hydroxyl 
group so as to prevent cyclisation.
Fig. 4.4 Preparation of 3-iodopropyltetrahydropyranyl ether
3-Bromopropan-l-ol was readily reacted with dihydropyran 
(Niyashita, et al, 1977) and the resulting 3-bromopropyltetrahydro- 
pyranyl ether obtained as a colourless oil. This alkyl bromide was 
converted into the corresponding alkyl iodide, by treatment with sodium 
iodide in acetone at reflux (Diana, et al. 1977), in good yield (Fig. 
4.4). Thus this route appears to be more suitable for the preparation
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of the protected alkyl iodides than direct reaction of the appropriate 
iodoalcohol with dihydropyran.
The prerequisite broaoalcohols may be prepared by the cleavage of 
cyclic ethers, using the method of Long and Freeguard (1964), using 
bromine instead of iodine. Tetrahydrofuran yielded 4-bromobutan-l-ol in 
good yield which did not cyciise readily at room temperature.
4.5 Conclusions
Intramolecular alkylation of the thallium(I) salt of 3-bis 
(diisopropylphosphono)-1-iodopropane occurs very rapidly to yield 
tetraisopropyl cyclopropane-1,1-bisphosphonate. The precursor to 
cyclisation can be prepared via alkylation of the thallium(I) salt of 
tetraisopropyl methylenebisphosphonate with 2-iodoethyltetrahydro- 
pyranyl ether followed by development of the protected hydroxyl group 
into an iodide functionality. This procedure should be readily adapted 
to the synthesis of cycloalkyl-1,1-bisphosphonates of other ring sizes.
4.6 Experimental
4.6.1 Preparation of t-Butyl Diethyl Phosphonacetate
This was prepared as described (Erion and Walsh, 1987) and was 
purified by distillation under vacuum at 82-83°C/0.25 mmHg (lit 115#C/2 
mmHg) to yield the title compound as a colourless oil (43.lg, 94%).
['H NMR (CDCla) 8 1.38(6H,t,J=6.8Hz),1.50(9H,s), 2.92 (2H,d,J =
21.7 Hz), 4.92 (4H,dq,J = 7Hz, J=7.8 Hz) p.p.m.; *«P NMR (CDCla) 6
24.1(f) p.p.m.; '»C NMR (CDCl*) 8 172(i), 81.8(a), 62.3 (d,J - 6.1 Hz), 
35.4 (d,J « 133 Hz), 27.7(a), 16.2 (d,J - 6.1 Hz) p.p.m.; Analyiii C, 
47.58; H, 8.61; P, 11.56%. C10H21O9P requires C, 47.62; H, 8.39; P,
12.28%; Mass spectrum (NHaCI) (M+H)* 253].
4.6.2 Preparation of t-Butvl Diethyl 1-Phosphonocvclopropane Carboxvlate 
This was prepared essentially as described (Erion and Walsh,
1987), via a phase transfer reaction of the above, except that a longer 
reaction time (24h) was found necessary. Flash chromatography on silica 
gel, eluting with chloroform, yielded the title compound as a colourless 
oil (4.9g, 59%).
t*H NMR (CDCla) 8 4.26 (4H, quint, J*7.5 Hz), 1.56 (9H,s), 
1.42(6H,t,J ■ 7.5Hz), 1.5-1.3 (4H,m) p.p.m.; **P NHR (CDClj) 8 25.1
(s) p.p.m.; **C NMR (CDCls) 8 170 (s), 81.7(s), 62.1 (d,J = 6.0Hz),
27.8 (s), 19.7 (d,J * 197 Hz), 16.2 (d,J = 6.0 Hz), 14.4(s) p.p.m.;
Analysis C, 51.56; H, 8.46; P, 9.96%. CiaHsaOsP requires C, 51.79; H, 
8.33; P.ll.13%; Mass spectrum (NHaCI) (M+H)* 279].
4.6.3 Preparation of Diethyl 1-Phosphonocyclopropanecarboxylic Acid 
This was prepared as described (Erion and Walsh, 1987) by the
hydrolysis of the above with cold (0°C) TFA to yield the title compound 
as a colourless oil (3.16g, 94%). This crystallised on standing; mpt
61-63#C (lit 65-67#C).
[*H NMR (CDCla) 8 4.24 (4H, quint, J = 7.4 Hz), 1.55 (2H,m,broad), 
1.50 (2H,m), 1.35 (6H,t,J = 7.4 Hz) p.p.m.; =»‘P NMR (CDCI3) 8 25.0(s) 
p.p.m.; Analysis C, 42.26; H, 6.63; P, 12.13%. CeHisOsP requires C, 
43.25; H, 6.81; P, 13.94%; Mass spectrum (NHaCI) (M+H)» 223].
4.6.4 Preparation of l-PI)osphonocyclopropanecarborylic tcid 
Bistcyclohexylannoniun) Salt
The diethyl ester above was dealkylated via the usual procedure 
(section 2.5.7) and the title compound was obtained pure by twice 
recrystallising from acetone-methanol (10:1)/diethyl ether and dried in 
vacuo over phosphorus pentoxide to yield a white solid (1.45g, 59%).
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I*H NMR (DsO) 5 3.16 (2H,m), 1.98 (4H,b ), 1.80 (4H,a), 1.65
(2H,m), 1.2-1.5 (lOH.m), 1.6-1.5 (4H,b ) p.p.m.; ="P NMR (D*0) 6
21.9(s) p.p.a.; ‘H coupled 8 21.9 (tt,J = 8.6 Hz, J = 9.1 Hz) p.p.m.; 
Analysis C, 51.69; H, 9.15; N, 7.36; P, 7.96%. CiaHaaNgOsP requires C, 
52.73; H, 9.13; N, 7.69; P, 8.50%].
4.6.5 Preparation of 2-Iodoethvltetrahvdropvranvl Ether
This was prepared by coupling 2-iodoethanol with dihydropyran in 
the presence of PPTS as described (Miyashita, et al, 1977). The product 
was purified by distillation under vacuum at 49-50#C/0.1 mraHg to yield 
the title compound as a colourless oil (31.2g, 94%).
[>H NMR (CDCla) 6 4.75 (lH,t,J = 3.4 Hz), 4.1 - 3.8 (2H,m), 3.80 
(lH.dt, J = 5.7 Hz, J = 6.9 Hz), 3.60 (lH,dt,J = 5.7 Hz, J = 6.9 Hz), 
3.35 (2H,t,J = 6.7 Hz), 2.0-1.5 (6H,m) p.p.m.; Analysis C, 32.44;
H,5.14; I, 47.73%. CtHi sIO* requires C, 32.83; H, 5.12; I, 49.56%; Mass 
spectrum (NHaCI) (M+H)‘ 257].
Note
PPTS was prepared according to the method of Miyashita, et al, (1977).
4.6.6 Preparation of 3-Bis(diisopropylphosphono)propvltetrahvdro- 
pyranyl Ether
Alkylation of tetraisopropyl methylenebisphosphonate with excess 
of the alkyl iodide synthesised above was carried out as described 
(Hutchinson and Semple, 1985). Chromatography on silica gel, eluting 
with acetone/petroleum ether (l:14v/v), followed by rechromatography, 
eluting with aethanol/diethyl ether (1:50*/*) returned a mixture of the 
title compound and tetraisopropyl methylenebisphosphonate (»1:1 by *H 
NMR) as a colourless oil (3.21g). A small sample was rechromatographed 
for NMR analysis but the remainder was used in the next stage without 
further purification.
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t'H NMR (CDCls) 8 4.80 (4H,m), 4.65 (lH,t,J = 3.3Hz), 3.90 
(2H,n), 3.50 (2H,m), 2.42 (lH,tt,J = 6.1 Hz, J = 24.4 Hz), 2.20 (2H,m,J 
= 6.1Hz, J = 16.4 Hz), 1.9 - 1.5 (6H,m), 1.38 (24H,dd,J = 6.1Hz, J = 2.8 
Hz) p.p.m.] .
4.6.7 Preparation of 3-Bis(diisopropylphosphono)propan-l-ol
The residue from above (1.6g) was treated with PPTS in ethanol as 
described (Miyashita, et al, 1977). Flash chromatography on silica gel, 
elution with methanol/diethyl ether (l:30v/v), yielded the title 
compound as a colourless oil (0.48g, 66%).
t'H NMR (CDCls) 6 4.73 (4H,m,J * 7.0 Hz, J = 7.4 Hz), 3.76 
(2H,t,J = 6.1 Hz), 2.36 (lH,tt,J = 6.1 Hz, J = 25 Hz), 2.12 (2H,tq, J *
6.1 Hz, J = 16.8 Hz), 1.33 (12H,dd,J = 7.0 Hz, J = 2.0 Hz), 1.31 
(12H,d,J = 7.0 Hz) p.p.m.; 3*P NHR (CDCls) 6 22.2(s) p.p.m.; Analysis 
C, 46.34; H, 8.82%. C i s H s ^ P s  requires C, 46.39; H, 8.82%; Mass 
spectrum (NHsCI) (M+H)* 389].
4.6.8 Preparation of 3-Bis(diisopropylphosphono)propyl Tosylate
The above alcohol (0.44g, l.lmmol) was dissolved in chloroform 
(5cm3). Pyridine (0.72cm3 , 9 mmol) and p-toluene sulphonyl chloride 
(0.43g, 2.2 mmol) were added. After 24h the mixture was dropped into 
aqueous hydrochloric acid (5%v/v) and extracted with chloroform (2 x 25 
cm3). The solution was dried, filtered and evaporated to yield a 
colourless oil. Flash chromatography on silica gel, elution with 
methanol/diethyl ether (l:40v/v), yielded the title compound as a 
colourless oil (0.44g, 72%).
[*H NMR (CDCls) 5 7.77 (2H,d,J - 8.4 Hz), 7.31(2H,d,J - 8.4 Hz), 
4.72 (4H,m ,J * 5.7 Hz), 4.23 (2H,t,J = 6.6 Hz), 2.42 (3H,s), 2.24 
(lH,tt,J = 6.2 Hz, J = 24 Hz), 2.20 (2H,m,J = 6.2 Hz, J = 6.6 Hz, J = 16 
Hz), 1.29 <24H,dd,J = 5.7 Hz, J = 1.0 Hz) p.p.m.; 3*P NMR (CDCls) 5
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20.2 (s) p.p.m.; Analysis C, 50.73; H, 7.83%. C**H«oO»PaS requires C, 
48.70; H, 7.43%; Hass spectrum (NHsCI) (M+H)* 543].
4.6.9 Preparation of 3-Bis(diisopropylphosphono)-1-iodopropane
The above ester (0.41?, O.75mmol) was dissolved in dry acetone 
(10cm3). Anhydrous sodium iodide (0.56g, 3.8mmol) was added and the 
mixture refluxed under nitrogen for lh. The mixture was filtered 
through celite and the filtrate stripped in vacuo. Flash chromatography 
of the residue on silica gel, eluting with methanol/diethyl ether (1:40 
v/v), yielded the title compound as a colourless oil (0.27g, 73%).
[>H NMR (CDCls) 8 4.77 (4H,m,J = 6.4 Hz, J = 6.5 Hz), 3.46 
(2H,t,J = 7.2 Hz), 2.35 (2H,m,J = 6.2Hz, J = 7.2 Hz), 2.32 (lH.tt.J =
6.2 Hz, J = 28 Hz), 1.34 (24H,td,J = 6.4 Hz, J = 1.7 Hz) p.p.m.; 3‘P NHR 
(CDCls) 6 22.2(b ) p.p.m.; Analysis C, 36.81; H, 6.89%. CigfosIOsPz 
requires C, 36.16; H, 6.68%; Mass spectrum (NHaCI) (M+H)‘ 499].
4.6.10 Preparation of Tetraisopropyl Cyclopropane-1,1-bisphosphonate
The above compound (0.25g, 0.5 mmol) in dry THF (10cm3) under
nitrogen was treated with a solution of thallium(I) ethoxide in THF 
(500jiil, 0.5 mmol of thallium(I) ethoxide) dropwise over 2 min. After 
stirring for 2h the reaction mixture was passed down a florosil column 
(2 x 10 cm) eluting with acetone/petroleum ether (1:1*/», 150cm3). 
Evaporation of the eluate and flash chromatography of the residue on 
silica gel, eluting with methanol/diethyl ether (l:40v/v), yielded the 
title compound as a colourless oil (0.13g, 70%).
[‘H NMR (CDCls) 8 4.68 (4H,m,J = 6.2 Hz, J = 7.7 Hz), 1.32 
(24H,dd,J = 6.2 Hz, J = 4.1 Hz), 1.31 (4H,t,J = 13.9 Hz) p.p.m.; 3«P NMR 
(CDCls) 8 23.5(s) p.p.m.; '3C NMR (CDCls) 8 70.9(s), 24.0(s), 11.6
(t.J = 181 Hz), 10.8 (s) p.p.m.; Analysis C. 47.79; H, 8.20%;
Ci 9H3sO*P* requires C, 48.64; H, 8.71%; Mass spectrum (NHsCI) (M^H)• 
371.1707 (Ci9H330«P2 calc. 371.17 53)].
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4-6.11 Preparation of Tris(cvclohexvlaBmonium) Cyclopropane-1
1-bisphosphonate
The above ester was dealkylated via reaction with bromotrimethyl- 
silane and the product converted into its tris(cyclohexylammonium) salt 
as described (section 2.5.7}. Recrystallisation from methanol/diethyl 
ether yielded the pure title compound as a white solid (83mg, 59%).
P H  NMR (D*0) 6 3.18 (3H,m), 2.0 (6H,m), 1.8 (6H,m), 1.65 (3H,m), 
1.1-1.5 (15H,m), 0.95 (4H,t,J = 14.2 Hz) p.p.m.; 3,P NMR (D20) 6
21.4 (s) p.p.m.; (1H coupled) 8 21.4 (quint,J = 14.2 Hz) p.p.m.;
Analysis C, 49.81; H, 9.20%. C2iH«tN306P2 requires C, 50.49; H, 9.48%].
4.6.12 Preparation of 3-Bromopropyltetrahvdropvranyl Ether
This was prepared by coupling 3-bromopropan-l-ol with dihydropyran 
in the presence of PPTS essentially as described (Miyashita, et al, 
1977). The product was purified by distillation under vacuum (60- 
62#C/0.3 mmHg) to yield the title compound as a colourless oil (66.2g, 
83%).
[«H NMR (CDCla) 5 4.66 (lH,t,J = 7.8 Hz), 3.91 (2H,dt,J = 6.8 Hz, 
J = 10.6 Hz), 3.68 (2H,t,J = 6.8 Hz), 3.66 (2H,dt,J = 6.0 Hz, J = 10.0 
Hz), 2.16 (2H,quint,J = 6.8 Hz), 2.0-1.5 (6H,m) p.p.m.; Mass spectrum 
(El) (M)* 222,224; Analysis C, 44.19; H, 7.17%. CeHisBrOa requires C, 
43.07; H, 6.78%].
4.6.13 Preparation of 3-Iodopropyltetrahydropyranyl Ether
A mixture of the above compound (66.2g, 0.3 mol) and anhydrous 
sodium iodide (60.Og, 0.4 mol) in dry chloroform (400 cm3) under 
nitrogen was refluxed for 2h. After filtering through celite the 
solvent was stripped in vacuo and the residue partitioned between 
chloroform (500 cm3) and water (250 r»3). The chloroform layer was
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dried, filtered and the solvent evaporated. Distillation under vacuum 
(60-61#C/0.01mmHg) yielded the title compound as a colourless oil 
(67.5g, 84%).
[*H NMR (CDCls) Ô 4.65 (lH,t,J = 3.6Hz), 3.85 (2H,m,J « 6.0Hz, J 
* 10.0 Hz), 3.5 (2H,m,J * 6.5 Hz, J ■ 10.5 Hz), 3.32 (2H,t,J = 6.5 Hz). 
2.12 (2H,quint,J = 6.5Hz), 2.0-1.5 (6H,m) p.p.m.; Analysis C, 35.27; H, 
5.77; I, 46.81%. CgHl9IO* requires C, 35.57; H, 5.60; I, 46.98%; Mass 
spectrum (El) (M)** 270].
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CHAPTER 5
THE REACTION OF TRIALKYL PHOSPHITES WITH THIOPHOSGENE
5.1 Introduction
Carbonylbisphosphonic acid expresses significant in vitro anti­
influenza activity at concentrations lower than most pyrophosphate 
analogues (Cload and Hutchinson, 1983). This compound is also found to 
be an inhibitor of a number of other viruses such as hepatitis B, herpes 
virus, human cytomegalovirus (Oberg, 1983), avian myoblastosis virus 
(Eriksson, et al, 1982a) and most recently human T-lymphotropic virus 
type III (HTLV-III) (Vrang and Oberg, 1986); the causative agent of 
AIDS. Methods for the preparation of carbonylbisphosphonic acid and 
analogues are thus of interest.
Only one literature synthesis of a tetraester of carbonyl­
bisphosphonic acid has been reported (Kabachnik and Rossiiskaya, 1957), 
claiming that tetramethyl carbonylbisphosphonate was prepared from 
trimethyl phosphite and phosgene. However, this publication was 
retracted in the following year (Kabachnik and Rossiiskaya, 1958). The 
expected Arbuzov reaction (section 2.1.1) does not take place but 
diethyl phosphorochloridate is the reaction product (Fig. 5.1(a)). This 
was confirmed experimentally.
Tetrasodium carbonylbisphosphonate may be prepared by the 
hydrolysis, in strong alkalai, of dichloromethylenebisphosphonate or 
dibromethylenebisphosphonate (Quimby, et al, 1967) (Fig. 5.1(b)).
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0(MeO)^P ♦  COCl2 ------- -  (MeO)2P — Cl ♦  MeCl ♦  CO
Fig. 5.1(a) The reaction of trimethyl phosphite with phosgene
Fig. 5.1(b) Preparation of tetrasodium carbonylbisphosphonate
This snail molecule has little scope for nodification apart froa 
exchanging the carbonyl oxygen aton for other functionalities. 
Replacement by a methylene unit yields ethenylidenebisphosphonic acid 
which is found not to be an inhibitor of influenza (table 7.5) and only 
a poor inhibitor of other viruses (table AIII). Thus the electron 
withdrawing nature of the carbonyl oxygen atom appears to be important 
for antiviral activity.
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Another possibility is replacement of the carbonyl oxygen atom by 
sulphur. The object of this study was to investigate the synthesis and 
possible antiviral activity of thiocarbonylbisphosphonic acid (Fig. 
5.1(c)). Thiocarbonylbisphosphonic acid tetraesters have only been 
mentioned once in the literature (Brokke and Stoffey, 1966) as the 
product of the reaction between triethyl phosphite and thiophosgene.
Fig. 5.1(c) Tetraethyl thiocarbcnylbisphosphonate
However, no experimental details for the preparation were given and no 
references cited. In this study the reaction of trialkyl phosphites 
with thiophosgene was investigated in an attempt to synthesise this 
compound.
5.2 Results
5.2.1 Intermediates In The Reaction of Trialkvl Phosphites With 
Thiophosaene
The reaction between triethyl phosphite and thiophosgene was found 
to be very exothermic and, unless performed at low temperature, a large 
mixture of species resulted. A wide range of molar ratios of trialkyl 
phosphite to thiophosgene were examined (2:1, 3:1, 4:1 or 5:1) but in no 
case could 0,0-dialkyl thiocarbonylbisphosphonate be detected by 31P NMR 
or mass spectroscopy. In a typical experiment trimethyl, triethyl or 
triisopropyl phosphite was added at -78°C to a solution of thiophosgene 
in THF and the reaction mixture allowed slowly to warm to room
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Fig. 5.2.1(a) Hie reaction of trialkyl phosphites with thiophosgene
temperature. Under these conditions phosphorus stabilised ylids were 
the predominate reaction products together with the corresponding fully 
esterified phosphorothio-substituted methanebisphosphonates (7-27% by 
®'P NMR) (Fig. 5.2.1(a)).
95
0
HCl/30min/0°C
or
O H O
R = Me,Et,Pr*
Fig. 5.2.1(b) Preparation of 0,0-dialkyl S-[bis(dialkoxyphosphinyl)- 
methyl phosphorothioates
The ylids appear to arise from one thiophilic addition and two 
carbophilic additions to thiophosgene. Both thiophilic additions (eg 
Corey and Winter, 1963; Corey, et al, 1965) and carbophilic additions 
(eg Yoneda, et al, 1977) to thiocarbonyl groups are well documented. 
When the reaction mixtures were treated with gaseous hydrogen chloride 
or heated 0,0-dialkyl S-[bis-(dialkoxyphosphinyl)methyl] phosphoro­
thioates were the only products detectable by 3,P NMR spectroscopy (Fig. 
5.2.1(b)).
Even employing doubly distilled thiophosgene it was impossible to 
obtain the ylids in a pure state. Some of the 0,0-dialkyl S-[bis- 
(dialkoxyphosphinyl)methyl] phosphorothioates were always present along 
with small amounts of dialkyl phosphites (2-5% by 31P NMR) and trialkyl
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phosphates (4-12% by 3,P NMR). These arise from the difficulty in 
removing all traces of water and hydrogen chloride from the 
thiophosgene. When the reaction was carried out deliberately using a 
sample of partially hydrolysed thiophosgene 0,0-dialkyl S-[bis- 
(dialkoxyphosphinyl)methyl] phosphorothioates were obtained directly but 
there was also an increase in the yields of dialkyl phosphite and 
trialkyl phosphate by-products.
5.2.2 NMR Studies of Ylids and Phosphorothioates
5.2.2.1 Ylid Structure
The 31P NMR spectra of the ylids formed were ABX systems 
with a large J(AB) (*J 120Hz) coupling and small J(AX), J(BX) (*J=3.5-
6Hz) couplings. For these compounds the signals centred at 5 (Pa )=
28,27.5 and 26 p.p.m. can be attributed to the phosphonate residues; 
the signals centred at 8 (Pb ) - 55,49.5 and 46.5 p.p.m. can be
attributed to the trialkoxyphosphonium residues (a higher shift as 
expected (Burgada, et al, 1980)) and finally the signals centred at 
8<Pc) = 30.5, 28.5 and 27 p.p.m. are consistent with the phosphoro- 
thioate residues present (Zimin, et al. 1983).
In the ,3C NMR spectra of the ylids the bridge carbon atom 
resonated as a triplet of doublets with *J(CPa ) z  *J(CPb ) = 220Hz,
*J(CPc) Z  4Hz and shifts in the range 9-14 p.p.m. These high field 
shifts and large coupling constants are consistent with a high degree of 
localisation of the negative charge on the bridge carbon atom (Gray, 
1973; Bottin-Strzalko, et al. 1978).
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Fig. 5.2.2.1 Structure of ylids formed in the reaction of trialkyl 
phosphites with thiophosgene
Phosphorothioate Structure
IRO,2Pay4 ^ IOR12
(ROI2Pb
,R o i2pay ^ N^ « R ) 2
' R0' 2^  I
0 Ar
R = Me.Et.Pr1 2J(HP) =2J(HP) = 26Hz3 D
J(HP) =11—  14-5Hz
Fig. 5.2.2.2(a) Structures of 0,0-dialkyl S-[bis-(dialkaxyphosphinyl)- 
methyl] phosphorothioates and nitrogen analogues
The 31P NMR spectra of the phosphorothioates were A2X systems. 
The doublets centred at 8 (P a ) * Ô(P») ~  19,16.5 and 15.5 p.p.m. are
attributable to the phosphonate residues and the triplets centred at 
5(Pc)~ 28,24 and 22.5 p.p.m. are consistent with the phosphorothioate 
residues (3J(PP) ~  12Hz). In the ,3C NMR spectra of the
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"i------ 1-------- 1-------- 1--------r
BO 28 26 24 22
Fig. 5.2.2.2(b) Fully coupled, broad band decoupled and selectively 
decoupled 51PM1R spectra of 0,0-dimethyl S-[bis(dimethaxy- 
phosphinyl)methyl) phosphorothioate
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phosphorothioates the bridge carbon atom in each case resonated as a 
triplet of doublets with *J(CPa ) * >J(CP«) =  140Hz, *J(CPc) 2S 4Hz with 
shifts in the range 35-39 p.p.m. The increased shift and lower coupling 
constant, relative to their respective ylids, being consistent with a 
loss of negative charge and change in hybridisation.
In the 1H NMR of the phosphorothioates the bridge proton was found 
in each case to resonate as a quartet, implying an equivalence of the 
*J(HP) and 3J(HP) couplings ( ~  22Hz). Simplification of the fully 
coupled *‘P NMR spectrum of Pc occurred upon selective irradiation of 
the bridge proton in 0,0-dimethyl S-[bis-(dimethoxyphosphinyl)-methyl] 
phosphorothioate indicating the 3J(HPc) coupling to be 21Hz; a typical 
* J(HP) value. (Fig. 5.2.2.2(b)).
During selective irradiation of the isopropyl methine protons in 
0,0-diisopropyl S-[bis-(diisopropyloxyphosphinyl)-methyl] phosphoro­
thioate the 31P NMR resonance of Pc appeared as a doublet of triplets 
indicating 3J(HPc) to be 20Hz (slightly attenuated by an off-resonance 
effect). In nitrogen analogues of these compounds 3J(HP) couplings are 
smaller (11-14.5Hz) and in no reported examples are these equal to the 
1J(HP) couplings (Gross, et al. 1972) (Fig. 5.2.2.2(a)).
5.3 Reaction Mechanism
To ascertain the mechanism of the reaction leading to the ylids 
the reaction was followed by 31P NNR spectroscopy from -80#C to room 
temperature. The reactions of thiophosgene with triethyl phosphite and 
triisopropyl phosphite commenced at -80°C and the reaction with 
trimethyl phosphite commenced at -60#C. The intensity of the trialkyl 
phosphite resonance diminished until at -40#C (with an excess of 
thiophosgene) all the phosphite was consumed and species (29) (Fig. 5.3) 
were the main reaction products. 31P NMR data for these species are 
listed in table 5.3.
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Table 5.3 *‘P it« data of intermediates detected in the reaction of
trialkyl phosphites with thiophosgene
(R0LP-—  
3 d
(in THF)
•— ?«0R,3 -C r  
5— P (°R.2 
0
R Me Et Pr'
SP= 6P  (d) 
a d
46-26 4250 37-69
Sl> (t) 27-75 24-36 24-76
3J(pp)=3(pbp) 5-3 5-5 5*6
Above -40°C, for the reactions involving trimethyl and triethyl 
phosphite, the resonances due to species 29a and 29b decreased with the 
appearance of signals due to the ylids 30a and 30b (the production of 
traces of the corresponding phosphorothioates was detectable at the same 
time). In the case of the isopropyl ester the intermediate 29c was more 
stable and was dealkylated to the ylid 30c only at room temperature.
The production of the intermediates 29 arises from a mono- 
dealkylation of their probable precursors 28. In the 1 3C NMR spectrum 
of a mixture of triethyl phosphite and thiophosgene, maintained at
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a.
Fig. 5.
,C=S .  (ROI^ P IROIjP— C----P(OR)3 ,2 Cl
(ROUP----- -C----- PIORL
3 I 3
♦ .2 cr
s— p(or>3
-RCI
(ROIjP--- C ----PIORIj
S---- PIORL
0 i-RCl
II
(ROI-P----C---- PIORL
2 I 3
s — P(ORL
(28)
(30)
R = Me.Et.Pr1 
(a)(b)(c)
3 The mechanism of reaction of trialkyl phosphites with 
thiophosgene
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- 60°C, resonances due to the carbon atoms of ethyl chloride were 
observed. This dealkylation occurs exclusively at the 
trialkylphosphonium residue a  to the sulphur. Mo dealkylation of a 
trialkylphosphonium residue p to the sulphur was detectable by 31P NMR 
spectroscopy. Electronegative substituents attached to the phosphorus 
facilitate this reaction enabling it to occur at low temperature. This 
reaction is analagous to that of the salts [(R0)»P-S-C1J*C1“ which can 
eliminate RC1 at -30#C (Michalski, et al, 1978a).
The interaction of the thiocarbonyl group with trialkyl phosphites 
has been extensively studied and has been used synthetically in the 
synthesis of alkenes (eg Corey and Winter, 1963) and tetrathiofulvalenes 
(eg Krief, 1972). Thiophilic addition has also been reported to 
generate phosphorus ylids (Corey and Markl, 1967). All these reactions 
arise from a thiophilic addition of trialkyl phosphite to the
thiocarbonyl group and ylid formation implies reaction with a second 
equivalent of trialkyl phosphite leading to an 0,0*, O-trialkyl
thiophosphate. In the reaction of trialkyl phosphites with thiophosgene 
0,0*, 0*-trialkyl thiophosphates were never detected by 31P NMR 
spectroscopy; stable ylids being the result of nucleophilic attack, by 
chloride ions, on the alkoxy substituents at phosphorus. Analogous 
ylids are formed without desulphuration from the reaction of aryl 
chlorodithioformates with trialkyl phosphites (Birum, 1963) (Fig. 5.4).
5.4 The Reaction Of Phenyl Chlorodithioformate with Trimethyl
Phosphite
The patent described above (Birum, 1963) did not report NMR data 
for the ylid 31 (Fig. 5.4), thus the reaction between phenyl
chlorodithioformate and trimethyl phosphite was investigated by 31P NMR 
spectroscopy to compare the NMR of 31 with those of the ylids 30a— c 
(Fig. 5.3).
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(32)
Fig. 5.4 The mechanism of reaction of phenyl chlorodithioformate with 
trimethyl phosphite
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The reaction commenced slowly at -20»C with, in the 3*P NMR 
spectrum, a pair of doublets at 6 48 p.p.m. ((MeO)aP.) and at 5 31 
p.p.m. ((MeO)tP(O)-S-), consistent with the ylid 31, becoming apparent. 
The reaction was complete after 24h at room temperature when in addition 
to species 31, 32 could be detected by 31P NMR (7%) along with dimethyl 
phosphite (2%) and trimethyl phosphate (4%).
Harming the ylid 31 or treatment with gaseous hydrogen chloride in 
dichloromethane resulted in complete conversion to species 32. Thus the 
ylid 31 behaves in an analogous manner to those formed from trialkyl 
phosphites and thiophosgene in that a protonation-dealkylation reaction 
occurs rather than migration of an alkyl group from the trialkoxy- 
phosphonium residue to the ylid carbon, which has previously been 
observed (Middleton and Sharkey, 1964; Corey and Markl, 1967).
5.5 Conclusions
The reaction between trialkyl phosphites and thiophosgene, even 
when carried out at low temperature, does not lead to the expected 
esters of thiocarbonylbisphosphonic acid. The products of the reaction 
are stable ylids formed by two carbophilic additions and one thiophilic 
addition of the trialkyl phosphite to thiophosgene. No desulfuration of 
the thiocarbonyl group was observed.
Phosphorus ylids have seen extensive use in the Vittig reaction 
(Gosney, 1979) and phosphorus stabilised carbanions are employed in the 
Wadsworth-Emmons reaction (Wadsworth, 1977). The ylids formed from the 
reaction of trialkyl phosphites with thiophosgene do not have much scope 
for use in the Wittig reaction due to their specialised nature.
Upon heating or treatment with dry hydrogen chloride the ylids are 
found to undergo protonation-dealkylation reactions to yield phosphoro- 
thio-substituted methane bisphosphonates. The mechanism for the thermal 
protonation-dealkylation reaction is unclear as the reaction occurred as
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readily for the methyl eater as for the ethyl and isopropyl esters. 
This mechanism has previously been discussed (Ogata, et al, 1974) but 
not elucidated.
5.6 Experimental
5-6-1 Preparation of 0,0-Dialkyl S-[(dialkoxyphosphinyl)__ (trialfcoxy-
phosphoranylidene) methyl] Phosphorothioates - General Procedure 
To a solution of thiophosgene (15 mmol) in dry THF (30cm3) 
maintained at -78°C under nitrogen was added trialkyl phosphite (30 
mmol) dropwise over 10 min. The solution was allowed to warm to room 
temperature over 16h. The solvent and excess thiophosgene were stripped 
in vacuo to yield a crude sample of the title compound as an orange oil. 
Full data for all phosphorus ylids prepared in this manner are listed in 
table 5.6.1. The ylids were always obtained with a small amount (7-27% 
by 3lP NMR) of the corresponding 0,0-dialkyl S-[bis-(dialkoxyphos- 
phinyl)-methyl] phosphorothioates.
5.6.2 Preparation of 0.0-Dialkyl S-[bis-(dialkoxyphosphinyl)-methyl] 
Phosphorothioates - General Procedure
The crude ylid from above was dissolved in dry dichloromethane 
(20cm3) and the solution cooled to 0°C and saturated with hydrogen 
chloride gas for 20 min. The solvent was stripped in vacuo and the
title compound isolated in crude form as an orange oil (83-95% by 31P 
NMR). The phosphorothioates prepared in this manner could be obtained 
pure by flash chromatography on silica gel, eluting with acetone, in 
~  50% yield. Full NMR data for phosphorothioates prepared by this 
procedure are listed below.
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Table 5.6.1 ItlR characteristics of 0,0-dialkyl S- [ (dialkcocypfosphinyl) 
(trialkcocyphosphoranylidene) nethyl] phosphorothioates
0
__¡1
-“-S  1-°-tc
P" S- j i - i l0e"d3
0
2« |1 o 3 
S— A brl  
0
31P NMR(CDCl3) 3 ,P NMRICCy
6l>ldd)
6(>(dd)
6£(dd)
Me
2015
5S05
3068
Et
27-63
4969
2870
Pri
2590
46-69
2703
483(d)
308(d)
124 120 130 -
hw 55 56 6-0 -
%
35 53 60 33
,3C NMR1CDCI,! 13C NMRICCy
SC^td) 9-60 11-60 1370 1027(dd)
6C,(d) 5 57 0 6 7 6 4 6 0 6 7 ) 6770=60)
SCb(d) 51-6051) 6020=52 73607-0) -
SCc(d) 53-40x59) 62-40=6-2) 7010=701 -
Cj coupling constants
Me Et Pr'
JCP,JC | 220 222 223 268
Jc?
4 4 4 25
El CMI—
386 484 s .:
-
d) Prepared as described (Birum,1963)
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5.6.2.1. 0,0-Dimethyl S-[bis-(dimethoxyphosphinyl)-methvll
Phosphorothioate
t*H NMR (C*D») 5 3.2-3.9 (18H,m), 4.25 (lH,q,J « 22Hz) p.p.m.;
*‘P NMR (CDCla) 8 19.1 (d,J « 12Hz), 20.7 (t,J ■ 12Hz) p.p.m.; **C NMR
(CDCla) 835.3 (td,J - 139Hz, J - 4.3Hz), 54.4(m) p.p.m.; Analysis S,
8.62%. CtHi«0«PS requires S,8.72%; Mass spectrum (EI) Mt 371.9927 
(Ct HisOsPS cale. 371.9962)].
5.6.2.2 0,0-Diethyl S-ibis-(diethoxyphosphinvl)-methvl] 
Phosphorothioate
t1H NMR (CDCla) 8 1.38 (18H,t,J « 7Hz). 3.94 (lH,q,J - 22Hz), 4.13 
(4H,quint,J * 7Hz), 4.28 (8H,m,J ■ 7Hz) p.p.m.; *‘P NMR (CDCla) 8 16.7
(d,J - 12Hz) , 24.3 (t,J « 12Hz) p.p.m.; >9C NMR (CDCla) 8l6.4(m), 36.6
(td,J » 139Hz, J = 4.4Hz), 63.8(m) p.p.m.; Mass spectrum (EI) ( M ) t
456.0906 (CiaHaiOaPaS cale. 456.0901)].
5.6.2.3 0,0-Diisopropyl S-ibis-(diisopropoxyphosphinyl)-methvll 
Phosphorothioate
[«H NMR (CDCla) 8 1.40 (36H,d,J - 7Hz), 3.9 <lH,q,J - 22Hz), 4.5-
5.2 (6H,m) p.p.m.; **P NMR (CDCla) 8 15.6 (d,J * 12Hz), 22.5 (t,J »
12Hz) p.p.m.; **C NMR (CDCla) 8 24.0(m), 39.0 (td,J « 140Hz, J « 4Hz),
72.5(m) p.p.m.; Mass spectrum (EI) (M)! 540.1807 (CiaHaaOaPaS cale.
540.1804)].
5.6.3 Preparation of 0,0-Diethyl S-[(diethoxyphosphinyl) (thiophenyl) 
methyl] Phosphorothioate
This was prepared essentially as described (Birum, 1963) from 
phenyl chlorodithioformate and triethyl phosphite and treatment of the 
resulting phosphorus ylid with dry hydrogen chloride in dichloromethane
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at 0#C for 20 «in. Removal of the solvent in vacuo yielded crude title 
compound as an orange oil.
[‘H NMR (CDCla) 5 4.80 (lH,t,J = 16Hz) p.p.m.; *'P NMR (CDCla)
6 20.8 (d,J « 18Hz) , 22.5 (d,J « 18Hz) p.p.m.; *3C NMR (CDCla) 5 48.2
(dd,J = 155Hz, J « 4.3Hz) p.p.m.]
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CHAPTER 6
SYNTHESIS OF BISPHOSPHONATE ANALOGUES OF ARILDONE
6.1 Introduction
Through random screening studies 0 -diketones have been found to 
possess antiviral activity. These compounds are good chelators of metal 
ions; being used industrially in metal ion extraction from aqueous 
media (Burger, 1973). Lipophilic p-diketones and in particular arildone 
(4-[6-(2-chloro-4-methoxy)phenoxy]hexyl-3,5-heptanedione; Tig. 6.1(a)) 
possess in vivo activity against a range of viruses (NcSharry and 
Pancic, 1982).
Fig. 6.1(a) 17» structure of arildone
The mode of action of arildone remains unclear but metal ion 
chelation may be involved (Hutchinson, 1985). p-diketones are known to 
react with arginine groups in proteins (Kabayo and Hutchinson, 1977) 
which could result in inactivation of an essential viral protein, 
however it has been reported that in cell culture assays with arildone 
washing the cells readily reverses any inhibitory effect (Kim, et al, 
1980), so this seems an unlikely mode of action. It was also reported
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that, for herpes virus in cell culture, addition of arildone was only 
effective in reducing virus titre if the addition was carried out less 
than 6h post-infection (McSharry and Pancic, 1982). After this period 
of incubation addition of arildone had no effect. Arildone thus 
appeared to inhibit an early process in the infectious cycle such as 
cell penetration or viral uncoating. The extreme lipophilicity of 
arildone means that when administered in vivo it concentrates in the 
lipophilic bilayer of the cell wall where viral uncoating occurs. For 
general chemotherapeutic use arildone is insufficiently soluble in 
water. Its use is thus limited to cutaneous infections where it is 
usually applied topically as a cream in DMSO.
X=HCI
Fig. 6.1(b) Bisphosphonate analogues of arildone
The objective of this study was to prepare bisphosphonates 
resembling arildone and examine any antiviral activity (Fig. 6.1(b)). 
Compounds such as 33 may be regarded as both an analogue of arildone and 
also an analogue of inorganic pyrophosphoric acid. Substituted
methylenebisphosphonates which retain a halogen substituent on the 
bridge carbon atom possess in vitro activity against influenza virus and 
the addition of a large lipophilic side chain has been found to increase 
their activity in cell culture (Semple, 1986). This is because they are
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■ore readily taken up by cells than the parent bisphosphonic acids. 
Thus compounds such as 33 might be expected to express a range of 
activity by inhibiting RNA synthesis in viruses such as influenza and 
viral penetration or uncoating processes in viruses such as herpes and 
polio.
6.2 Synthesis of Bisphosphonate Analogues of Arildone
6.2.1 Synthetic Approach
The approach adopted is shown in Fig. 6.2.1. The preparation of 
the side chain has been described by Diana (Diana, et ai, 1977), thus 
the synthesis is reduced to the alkylation and halogénation of 
tetraisopropyl methylenebisphosphonate. Alkylation of the sodium salt 
of tetraisopropyl methylenebisphosphonate (Seyferth and Marmor, 1973) 
followed by reaction with sodium hypohalite (Curry, 1971) is one 
possibility to prepare the target molecule. However it is more 
effective to invert the two steps. Monohalogenation of tetraisopropyl 
methylenebisphosphonate cannot be accomplished in good yield but 
dichloromethylenebisphosphonate can be easily prepared (Quimby, et al, 
1968) and monodehalogenated by metal-halogen exchange (Seyferth and 
Narmor, 1973). Alkylation of the thallium(I) salt may then be 
accomplished in good yield (Hutchinson and Semple, 1985).
6.2.2 Results and Discussion
The procedures for dichlorination of tetraisopropyl methylene­
bisphosphonate (Quimby, et al, 1968) and monodehalogenation via metal 
halogen exchange (Seyferth and Harmor, 1973) both proceeded in good 
yield. The alkyl side chain was obtained as a 1:4 mixture of the 
corresponding bromide/iodide as described (Diana, et al, 1977) and could 
be used directly in alkylation experiments or could be further purified 
as described (section 6.4.6).
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riff. 6.2.1 Ite synthesis of bisphosphcnates related to arildcne
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Treatment of a solution of tetraisopropyl chloromethylene- 
bisphosphonate in THF with thallium(I) ethoxide yielded a white 
suspension of the thallium(I) salt as described (Hutchinson and Semple, 
1985). However treatment with a 10 molar excess of 1-(2-chloro-4- 
methoxyphenoxy)-6-iodohexane only resulted in a low (22%) yield of 
isolated product. In repeat experiments this yield could not be 
improved. Analysis of both the crude reaction product by 31P NMR 
spectroscopy and fractions obtained after flash chromatography indicated 
that alkylation of the thallium(I) intermediate was occurring but that 
this was followed by metal-chlorine exchange leading to cleavage 
products (Fig. 4.2(c)).
With tetraisopropyl bromomethylenebisphosphonate the thallium(I) 
salt could again readily be formed but none of the desired product could 
be obtained. Positive bromine abstraction and carbon-phosphorus bond 
cleavage were found to dominate the reaction. These increased problems 
with the thallium(I) salt of tetraisopropyl bromomethylene­
bisphosphonate can be equated with the fact that the carbon-bromine bond 
is weaker than the carbon-chlorine bond (Johnson, 1982) and that the 
first ionisation potential of bromine is less than that of chlorine 
(Downs and Adams, 1973).
With the thallium(I) salt of tetraisopropyl methylenebisphosphon- 
ate a 23% yield of the desired product was isolated. The absence of a 
bridge halogen atom resulted in less cleavage occurring but the excess 
thallium(I) ethoxide needed for complete anion formation was found to 
attack at phosphorus and exchange one of the ester groups of tetraiso­
propyl methylenebisphosphonate to ethyl. This was observed previously 
(section 4.3.2.1).
The problems encountered can be attributed to the reduced mobility 
of the large alkyl iodide under the reaction conditions. Thus the 
desired reaction proceeds more slowly and side reactions occur. The two 
substituted methylenebisphosphonates obtained were readily deesterified
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deesterified with bromotrimethylsilane and isolated as sodium salts via 
cation exchange chromatography (sections 6.4.9, 6.4.10).
6.3 Conclusions
C-Substituted methylenebisphosphonates which are analogues of 
arildone may be synthesised . via alkylation of thallium(I) salts 
(Hutchinson and Semple, 1985) of tetraisopropyl methylene and chloro- 
nethylenebisphosphonate but only in low yield. Despite this problem the 
products are readily isolated from the crude reaction mixtures by flash 
chromatography and deesterified by reaction with bromotrimethylsilane 
and this remains the method of choice for their preparation.
6.4 Experimental
6.4.1 Preparation of Tetraisopropvl Hethvlenebisphosphonate
This was prepared essentially as described (Roy, 1966). The title 
compound was obtained pure by distillation under vacuum (100-103*0/0.25 
mmHg) as a colourless oil (81.Og, 47%).
I*H NMR (CDCls) Ô 4.80 (4H,m,J = 6Hz), 2.40 <2H.t.J = 22Hz). 1.36 
(24H,dd,J = 6Hz) p.p.m.; *«P NMR (CDCls) 6 18.1(s) p.p.m.; Analysis 
C, 44.^5; H, 8.84%. CisHsoOsP* requires C, 45.35; H, 8.78%; Mass 
spectrum (NHsCI) (M+H)* 345].
6.4.2 Preparation of Tetraisopropvl Dichloromethylenebisphosphonate
This was prepared essentially as described (Quimby, ef al, 1968). 
The title compound was obtained pure by distillation under vacuum (112— 
115*0/0.1 mmHg) as a colourless oil (18.9g, 72%).
[*H NMR (CDCls) Ô 4.88 (4H,m), 1.41 (24H,d,J * 7.8Hz) p.p.m.; 3,P
NMR (CDCls)§ 6.7(s) p.p.m.; Mass spectrum (NHsCI) (M+H)‘ 413,415,417].
6-4.3 Preparation of Tetraisopropvl Chloromethylenebisphosphonate
This was prepared by the method of Seyferth and Marmor (1973) but 
using methyllithium in the place of butyllithium. The title compound 
was obtained pure by distillation under vacuum (109-lll°C/0.ImmHg) as a 
colourless oil (11.9g, 69%).
C* H NMR (CDCla) 6 4.86 (4H,m) , 3.92 (lH,t,J - 20Hz), 1.36
(24H,d,J = 8.0Hz) p.p.m.; »‘P NMR (CDCla) 6 11.5(s) p.p.m.; Mass
spectrum (NHaCI) (M+H)* 379,381].
6.4.4 Preparation of 2-Chloro-4-methoxyphenol
This was prepared as described (Brown, 1955). After distillation 
under vacuum (118-128<*C/15 mmHg) the distillate solidified and the title 
compound obtained pure, by recrystallisation from petroleum ether (bpt 
40-60°C), as colourless crystals (30.4g, 79%), mpt 44-46°C (lit. 46-
47°C).
['H NMR (CDCla) 5 7.1-6.7 (3H,m), 4.55 (1H,s,broad), 3.80 (3H,s)
p.p.m.; Mass spectrum (El) (M)1 158,160].
6.4.5 Preparation of 1-(2-Chloro-4-methoxvphenoxv)-6-bromohexane
This was prepared essentially as described (Diana, et al, 1977). 
The title compound was obtained pure by distillation under vacuum (148— 
152°C/0.2-0.3 mmHg) as a colourless oil (43.4g, 76%).
[‘H NMR (CDCla) 8 7.0 (lH,d,J * 2.5Hz), 6.92 (lH,d,J = 9.8Hz), 
6.80 (lH,dd,J = 2.5Hz, J = 9.8 Hz), 4.05 (2H,t,J = 6.5Hz), 3.80 (3H,s), 
3.50 (2H,t,J = 7Hz), 1.90 (4H,m), 1.60 (4H,m) p.p.m.; Mass spectrum
(El) (H): 320,322,324].
6 . * . 6  Preparation ot 1 - U-Cbloro-4-.etlio«YPl»i.oxY)-6-iodoheaane
This was obtained as a 4:1 mixture (by *H NMR) with the above 
bromide as described (Diana, et al, 1977). The title compound was
obtained in sufficient purity for the next step by distilling the alkyl
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bromide out of the mixture. >H NHR analysis of the residue indicated 
>95% of the title compound ( s: 30g, ~  60%) . This was used without 
further purification.
I'H NMR (CDCls) 6 6.98 (lH,d,J = 2.5Hz), 6.90 (lH,d,J = 9Hz),
6.75 (lH,dd,J = 2.5Hz, J = 9Hz), 4.0 (2H,t,J * 7Hz), 3.80 (3H,s), 3.24 
(2H,t,J = 7Hz), 1.85 (4H,m), 1.55 (4H,m) p.p.m.; Mass spectrum (El) (M)t 
368,370].
6-4-7 Preparation of___ Tetraisopropyl__ (2-Chloro-4-nethoxYphenoxyhexyl)
chloromethylenebisphosphonate
Alkylation of the thallium(I) salt of tetraisopropyl chloro­
methylenebisphosphonate was carried out essentially as described 
(Hutchinson and Semple, 1985). The title compound was obtained pure by 
flash chromatography on silica gel, eluting with acetone/petroleum ether 
(bpt 40-60°C) (1:12*/« changing to 1:2 */v after elution of the excess
alkyl iodide), and recrystallisation from petroleum ether (bpt 40-60#C) 
as a white solid (0.71g, 22%), mpt 68»C.
P H  NMR (CDCls) 8 6.92 (lH,d,J = 3Hz), 6.85 (lH,d,J = 9Hz), 6.73
(lH,dd,J * 9Hz, J = 3Hz), 4.88 (4H,m), 3.95 (2H,t,J = 7Hz), 3.75 (3H,s),
2.2 (2H,m), 1.80 (2H,quint,J = 7Hz), 1.72 (2H,quint,J = 7Hz), 1.50
(4H,m), 1.35 (2H,d) p.p.m.; ¡»‘P NMR (CDCls) 8 14.8(s) p.p.m.; *®C NMR
(CDCls) 8 153.8(s), 148.8(s), 123.7(s), 115.8(s), 115.l(s), 112.8(s) 
72.8(d,J = 21.4Hz), 70.0(s), 62.9 (t,J * 145Hz), 55.7(s), 36.0(s), 
29.5(s), 29.1(s), 25.6(s), 24.4(s), 23.8(dd,J « 16Hz, J = 69Hz) p.p.m.;
Analysis C, 50.49; H, 7.22%. C2«H«*ClsO.P2 requires C, 50.41; H, 7.48%; 
Mass spectrum (El) (N)t 618,620,622].
®-4-8 Preparation o|___ Tetraisopropyl (2-Chloro-4-methoxyphenoxyhexyl)
methylenebisphosphonate
Alkylation of the thallium(I) salt of tetraisopropyl methylene­
bisphosphonate was carried out as described (Hutchinson and Semple,
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1985). The title compound was obtained pure by flash chromatography on 
silica gel, eluting with acetone/petroleum ether (bpt 40-60°C) 1:15"/* 
changing to 1:5 */v after elution of the excess alkyl iodide), as a 
colourless oil (0.79g, 23%).
H NMR (CDCla) 5 6.95 (lH,d,J = 2.5Hz), 6.85 (lH,d,J = 9.5Hz),
6.75 (lH.dd,J - 9.5Hz, J = 2.5 Hz), 4.80 (4H,m), 3.96 <2H,t,J = 6Hz),
3.76 (3H,s), 2.1-1.4 (10H,M), 1.35 (24H,d,J « 7.5Hz) p.p.a.; »‘P NMR
(CDCla) 622.0(s) p.p.m.; ‘®C NMR (CDCla)8 153.6(s), 148.6(b ), 123.5(a), 
115.6(s), 114.9(8), 112.5(s), 70.5(dd,J = 7Hz, J = 15Hz), 69.7(s), 
55.4(s), 38.1(t,J = 135 Hz), 28.9(s), 28.8(s), 25.5(s), 25.3(s), 
23.9(s), 23.7(dt,J - 29Hz, J - 4Hz) p.p.m.; Analysis C, 51.49; H, 8.04; 
P, 9.94%. C**H«?C10«P* requires C, 53.38; H, 8.10; P, 10.59%; Mass
spectrum (NHaCI) (M+H)♦ 585,587].
6.4.9 Preparation of Tetrasodium (2-Chloro-4-methoxyphenoxyhexyl)- 
chloroaethylenebisphosphonate
The tetraisopropyl ester was deesterified essentially as described 
(section 2.5.7) except that the crude acid was passed down a short 
column of dowex 50 cation exchange resin (Na‘ form). Lyophilisation of 
the eluate yielded the title compound as a white solid (0.39g, 68%).
i‘H NMR (Da0/Ds-pyridine, 1:1*/«) 8 7.1 (3H,m), 4.05 (2H,t,J =
7Hz), 3.95 (3H,s), 2.9 (2H,m), 2.3 (2H,m), 1.85 (2H,m), 1.6 (4H,m)
p.p.m.; 3,P NMR (DaO/Da-pyridine, 1:1'/*) 8 16.1(s) p.p.m.; Analysis
C, 31.24; H, 4.46; P, 11.75%. CnHi.ClaO.PaNa« requires C, 31.19; H, 
4.37; P, 11.49%].
6.4.10 Preparation Of Disodium (2-Chloro-4-methoxyphenoxyhexyl)- 
methylenebisphosphonate
The tetraisopropyl ester was deesterified as above to yield the 
title coapound as a white solid (0.37g, 76%).
118
[‘H NMR (D2O/D9 - pyridine 1:1*/«) 6 6.55 (3H,b ), 3.58 (2H,t,J
7Hz), 3. 45 (3H,s) , 2.0 (lH.td.J » 20Hz, J « 10Hz), 1.95 (2H,b ), 1.60
(2H,n), 1.40 (2H,n) , 1.20 (4H,m) p.p.m.; ®‘ P NMR (DsO/Ds - pyridine.
1 : 1 * / » ) 6 21.0(B) p.p.m.; Analysis C, 36.44; H, 4.65%. Ci4H n C 10«PsNa2
requires c . 36.50; H, 4.16%].
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CHAPTER 7
THE ACTIVITY OF HETHYLENEBISPHOSPHONATES AGAINST 
INFLUENZA VIRUS
7.1 Introduction
The ability to disrupt the viral protein envelope of influenza 
with detergent without interruption of the RNA polymerase activity 
allows this activity to be examined. Under suitable conditions a 
detergent disrupted suspension of influenza will synthesise viral RNA. 
The extent of production of RNA can be measured by recording the extent 
of incorporation of [3H]-UTP into acid-precipitable material. Assaying 
for polymerase activity both in the presence and absence of potential 
inhibitors allows IDso values for the compounds to be determined.
In infecting a cell influenza uses a cleaved section of cellular 
RNA to prime viral mRNA synthesis. Under cell-free conditions this is
not possible hence it is necessary to add ApG to the assay solutions to 
act as a primer. ApG is known to be an effective primer for influenza 
(Kawakami, et al, 1981) and it is noticeable that the coupling of 
adenosine (A) to guanosine 5*-triphosphate (GTP) yielding the ApG 
linkage and pyrophosphoric acid is the first reaction of the chain 
elongation phase of viral mRNA synthesis (Fig. 1.1.2.2.1(a)).
In this study the bisphosphonates synthesised were assayed against 
the RNA polymerase of influenza A/X49 via a cell free assay in the 
presence of ApG to act as a primer.
7.2 Preparation of Influenza Virus Suspension
The virus used for determining the inhibitory abilities of the 
pyrophosphate analogues synthesised was influenza A/X49 and was grown in 
the chorioallantoic membrane of fertile hens eggs essentially as 
described (Kelly and Dimmock, 1974).
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Eleven day old fertile hens eggs (64) were each innoculated with 
infected allantoic fluid (100 )il of a 1 x 10'3 dilution in PBS) and 
incubated (33*C/48h). The eggs were then chilled (-20»/2h) and the 
allantoic fluid was collected (all further procedures were carried out 
at 0-4°C). Unwanted egg membranes were removed by centrifugation (3,000 
r.p.m./20 min.) and the crude virus pelleted by centrifugation (21,000 
r.p.m./90 min/6 x 300cm3 rotor). The supernatant was discarded and the 
pellet soaked in PBS (10cm3/18h).
The pellet was suspended in PBS (10 cm3) (the presence of virus 
checked by a haemagglutinin assay (Dinmock, 1987)) and the solution 
applied onto a velocity gradient of 15-45% (-/,) sucrose in buffer 
(60cm3, 10 mM tris-HCl. pH 7.4) and centrifuged (22,000 r.p.m./lh/3 x 
65cm3 swing out rotor). The diffuse virus band was collected by bottom 
puncture and diluted with PBS to a final volume of 30cm3 .
The solution was applied onto an equilibrium gradient of 30-70% 
(w/v) sucrose in buffer (50cm3, lOmM tris-HCl, 150 mM NaCl, pH 7.4) and 
centrifuged (20,000 r.p.m./18h/3 x 65cm3 swing out rotor). The virus 
band was again collected, diluted with PBS, and the virus pelleted by 
centrifugation (30,000 r.p.m./2h/8 x 50cm3 rotor). The supernatant was 
then discarded and the virus pellet soaked in PBS for 18h.
The virus pellet was resuspended in buffer (400 jxl. 400uM tris- 
HCl, pH 8.0) and frozen in aliquots (30 jjI) at -70°C. Each aliquot was 
thawed immediately before use.
7.3 Influenza Virus Polymerase Assays
These were carried out essentially as described (Cload and 
Hutchinson, 1983). RNA polymerase activity was assayed in a standard 
reaction mixture (200 ^ il) containing 50mM tris-HCl buffer, pH 8.0; 5mM 
magnesium acetate, 150mM potassium chloride; 5mM dithiothreitol; 0.4mM
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adenylyl (3*-5*)-guanosine (ApG), 0.25% (v/v) Nonidet-P40, 0.4mM each of 
ATP, CTP and GTP and [»HJ-UTP (5 ^ iCi, 3H incorporatd at the 5-position) 
and purified virus suspension (30jil).
The mixtures were maintained at 0-4°C until RNA synthesis was 
initiated by the addition of virus suspension. The mixtures were 
incubated during which time the incorporation of tritium into acid- 
precipitable material increased linearly. Polymerisation was stopped by 
the addition of cold (0°C) saturated tetrasodium pyrophosphate solution 
(200jil) and the mixtures added to cold (0#C) TCA (2cm3 , 10% w/*). After 
thorough agitation the solutions were maintained at 0-4#C for >12h.
Precipitated material was collected on Whatman GF/C glass fibre 
discs, prewetted with cold (0°C) TCA (10% w/v), which were washed with 
cold TCA (10% w/v, 3 x 5cm3), ethanol (5cm3) and diethyl ether (2 x 
5cm3). After thorough drying the radioactivity of each disc was 
determined by scintillation counting using a xylene-based scintillant.
The pyrophosphate analogues under test were added to the reaction 
mixtures before the addition of virus suspension and all reactions were 
performed in duplicate. For each analogue tested a semilogarithmic 
dose-response curve was drawn and the concentration of the analogue 
which inhibited by 50% the incorporation of [3H]-UTP into acid- 
precipitable material was determined (IDso).
7.4 Determination of Zinc Binding Constants
In view of the report (Cload and Hutchinson, 1983) that a 
correlation exists between the ability of pyrophosphate analogues to 
bind zinc and their inhibition of influenza under cell free conditions, 
the abilities of selected compounds to bind zinc were examined.
The zinc binding constants were determined by the method of Hummel 
and Dreyer (1962) using a column of Sephadex G-10 (1.6 x 96cm) which was 
equilibriated with zinc chloride (10 jjM) in triethanolamine-HCl buffer 
(0.1M, pH 8.0; the same pH as the assay solutions). The analogues
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(100-200 nmole) were loaded onto column in triethanolamine/zinc buffer 
(2cm3) and the column eluted with the same buffer. The zinc content of 
individual fractions was determined by atomic absorption spectrometry 
and the zinc binding constants determined. Full details of this 
technique have been described by Yoza (1977).
7.5 Results
7.5.1 Inhibitory Effects Against Influenza RNA Polymerase
Table 7.5 shows the IDso values of all the methylene- 
bisphosphonates tested. A typical dose-response curve, for the 
inhibition of incorporation of [3H]-UTP into acid-precipitable material 
during influenza RNA synthesis, is shown in Fig. 7.5.1.
7.5.2 Zinc Binding Constants
All the zinc binding constants determined as described (section 
7.4) are listed in Table 7.5.
7.6 Discussion
In this study the IDso values reported relate to the inhibition of 
the total of the RNA polymerase activity by 50%. The kinetics of the 
inhibition of the RNA polymerase activity of influenza are very complex 
(Cload, 1983) and the individual stages of the process have not been 
fully characterised.
Monofluoromethylenebisphosphonic acid expressed the greatest 
activity of the halogenated methylenebisphosphonic acids studied with 
dif luoromethylenebisphosphonic acid and fluorobromomethylenebisphos- 
phonic acid also showing good activity. It is noticeable that all of 
the halageno- and dihalagenomethylenebisphosphonates so far examined in 
this study and previously (Cload, 1983; Semple, 1986) exhibit activity 
against the RNA polymerase of influenza except the parent compound; 
methylenebisphosphonic acid.
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Table 7.5 Activity of methylenebisphosphcnates and related ccmpcunds 
against influenza RNA polymerase
C0MP0UN0
I0 50
(>j M)
TRIS C__J  2 SALT R=-PI0H)2
(ZnJ,l
1) R----- — R 130 >  6
(Tetrasodium sait) (120) >  6
21 R— CHF— R3 85 >  6
3) R— CFBr— R 115 >  6
4) R------C— R
" H2
470[S0Olh *
S)
R - j —
0
20 54
6) R— CH— R > 5 0 0 4-9
CH2SEt
7) R-----CH— R > 5 0 0 -
C H jS P r
8) -ço 390 "
9)
" - A “ *
CH2CH2
> 5 0 0 -
10) R— C H j - R 1 > 5 0 0 5 3
11) 320 -
CH2CH2
12) R— C H j— COjH1 275 55
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13)
CH2CH2
>500 -
14) R-CHjCHjCOjH1 > 500 4
15) c t f > 500 59
16) R— CH---Rf
SMe
170 ■
17) R---CH---R*'9I
o = s - *
0
60
18) R— CH---R Cl
^ O - ^ ^ O M e
> 5 00
'
19) R—iCI— R n 450 58
a) Assay performed on free acid
b) Assay performed on tetrasodium salt
c) Cload and Hutchinson,(1983)
d) Assay performed on bis(cydohexylammonium) salt
e) Prepared as described in appendix I
f) Kindly donated by Dr S Masson, I.S.M.R.A.,Universite de Caen
g) Assay performed on tetratrimethylsilyi ester
h) Repeat assay
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It has been argued by Blackburn (1981) that in the use of 
bisphosphonates as analogues of inorganic pyrophosphoric acid emphasis 
should be placed as much on their isopolar properties as their isosteric 
properties. Methylenebisphosphonic acid is a good isostere of 
pyrophosphoric acid; the distance between the two phosphorus atoms in 
pyrophosphate (0.294nm) and methylenebisphosphonate (0.305 nm) differing 
by less than 4% (Larsen, et al, 1969); but shows no activity.
Substituting the bridge carbon atom with electron withdrawing 
halogen atoms reduces the dissociation constants of the methylene­
bisphosphonic acid such that it more closely mimics the behaviour of 
inorganic pyrophosphoric acid in solution. Fluorination of the 
methylene bridge has a large effect on the dissociation constants. The 
acid dissociation constants of difluoromethylenebisphosphonic acid have 
been accurately determined and mimic closely those of inorganic
pyrophosphoric acid (Table 7.6). It thus appears that the activity of 
the halogenated methylenebisphosphonic acids is related to the fact that 
they are both isopolar and isosteric with pyrophosphoric acid.
Hethylenebisphosphonates lacking electron attracting bridge 
substituents (eg 6-10 , 18 ) showed little or no activity against the 
influenza RNA polymerase as would be expected for the reason discussed 
above. The sulphone (17) was more active than its deoxygenated analogue 
(16) but this compound is unstable in solution (decomposing over several 
days). It was added to the assay solutions directly as its
tetratrimethylsilyl ester (hydrolysis in situ yielding the free acid) 
and interference in the assay by the other product of hydrolysis, 
tetratrimethylsilyl hydroxide, has not been ruled out.
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ACTIVITY
Fig. 7.5.1 Hie inhibition of influenza A/X49 RNA polymerase by 
monofluoranethylenebisphosphcnic acid.
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Table 7.6 Acid dissociation constants of inorganic pyrophosphoric acid
and related compounds
COMPOUND
0
R = -P(0H)2
pK, pK2 pK3 PK4
R---- 0 — R a _ 2 36 577 822
R— CH— R a - 287 745 1096
R—  CHF— R—(l  
'  b : <27278 615662 93510-1
c 144 211 566 7 63
R— CF?— R— ( d 146 214 5-78 816
a - <26 580 800
R-CC>F-R-<e ; - 6-116-1 97898
R— CHBr-R e - 2-20 66 102
a) Blackburn,et al(1986a) d) Fonong, et all1983)
b) McKenna and Shen(1981) e) Grabenstetter, etal(196 7)
c) Burton, et al(1982b)
The arildone analogue (19) showed considerably less activity than 
monochloromethylenebisphosphonic acid (ID5Q = 86 Jim t Semple, 1986). 
This contrasts with the situation in cell culture where halogenated 
methylenebisphosphonic acids bearing lipophilic side chains are more 
active than those without (Semple, 1986).
Increasing the rigidity of the analogue, by enclosing the bridge 
carbon atom in a cyclopropane ring, had no significant effect on the 
activity of the compound. The cyclopropyl analogue (9) of methylene­
bisphosphonic acid (10) had no activity and the cyclopropyl analogue (11) 
of phosphonoacetic acid (12) retained most of the activity of 
phosphonoacetic acid.
The three fluorinated »-ompounds assayed (1-3), which were all good 
inhibitors of influenza, were found to have zinc binding constants of
>6. It has been shown previously that bisphosphonates that bind zinc 
this effectively are good inhibitors of influenza (Cload and Hutchinson, 
1983) and this lends weight to the possibility that their mode of action 
is via chelation to an essential zinc ion present in the RNA polymerase. 
This enzyme is also known to be dependent on the presence of magnesium 
ions but it is unlikely that the compounds exhibit their activity by 
removing essential magnesium ions from solution. In the assay solutions 
magnesium ions are present at a concentration of 5mM but some of the 
compounds assayed were active at concentrations less than IOOjiM and 
dibromomethylenebisphosphonic acid is reported to be active at IO^ iM 
(Cload and Hutchinson, 1983).
7.7 Conclusions
It is concluded that C-substituted methylenebisphosphonic acids 
are effective inhibitors of the RNA polymerase of influenza virus only 
when substituted with one or more electron withdrawing groups. In these 
cases their behaviour in solution more closely mimics that of inorganic 
pyrophosphoric acid. Isopolar considerations appear to be equally, if 
not more, important than isosteric ones and that the inhibitory effect 
appears to be related to the ability to bind zinc under physiological 
conditions.
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APPENDIX I
SYNTHESIS OF BENZENE-1,2-BISPHOSPHONIC ACID
AI.l Preparation of 1,2-Bis(dimethoxyphosphoryl) benzene
This was prepared by a modification of the procedure described by 
Kyba (1983). A mixture of trimethyl phosphite (263g, 2.12 mol) and 1,2- 
dichlorobenzene (94g, 0.64 mol) was photolysed with a mercury emission 
lamp (50V, = 254nm) in a quartz apparatus for 130h. Lyophilisation and
cooling (-20°C/2h) yielded a white precipitate which was collected by 
filtration. Recrystallisation from acetone yielded the title compound 
as a white crystalline solid (7.5g, 3.4%).
t1H NMR (CDCls) 6 8.18 (2H,m), 7.66 (2H,m), 3.85 (2H,d,J = 11Hz)
p.p.m.; 3«P NMR (CDCls) 5 18.3(s) p.p.m.; Mass spectrum (NHjCI) (M+H)*
295; mpt 75-78<>C (lit 79-81+C].
AI.2 Preparation of Benzene-1,2-bisphosphonic Acid
The above tetramethyl ester (2.0g, 6.8 mmol) was refluxed in
concentrated hydrochloric acid (25cm3) for 48h. After freeze drying the 
residue was recrystallised from chloroform to yield the title compound 
as a white crystalline solid (1.3g, 81%).
[>H NMR (DzO) 6 8.05 (2H,m), 7.73 (2H,m) p.p.m.; 3«P NMR (D*0) 5 
19.1(s) p.p.m.; Mass spectrum (NHaCI) (M+H)* 239; Analysis C, 30.02; 
H, 3.11; P, 24.93%. CeHeOeP* requires C, 30.27; H, 3.39; P, 26.02%].
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APPENDIX II
INHIBITION Of HIV/HTLV-III BY PYROPHOSPHATE ANALOGUES
All.1 Introduction
The rapid world-wide increase in cases of acquired immune 
deficiency syndrome (AIDS) has greatly increased the need for compounds 
with broad spectrum antiviral activity. The causative agent, human T- 
lymphotropic virus type III (HTLV-III), or as also known: human 
immunodeficiency virus (HIV) has an affinity for human T-cells whose 
destruction causes immunocompromisation. This often results in 
adventicious infection by other viruses.
HTLV-III possesses a reverse transcriptase activity and this has 
been found to be inhibited by both carbonylbisphosphonic acid and phos- 
phonoformic acid (Vrang and Oberg, 1986; SandstrOm, et al, 1985). The 
mode of action of these compounds is unknown but in view of their 
probable mechanisms of action against influenza and herpes it is 
possible that they inhibit the reverse transcriptase by binding to an 
essential metal ion.
In vitro phosphonoformic acid has been reported to be active in 
concentrations as low as 0.5jtH (Vrang and Oberg, 1986). This has 
prompted compassionate use of this compound in severely 
immunocompromised patients (Oberg, et al, 1987). In vivo activity was 
indeed observed but the very high doses required (median 6-*10g/day) 
caused undesirable side effects, although these nust be weighed against 
the unfavourable prognosis of these patients.
In view of these results selected compounds were assayed against 
the reverse transcriptase of HTLV-III and the results are listed in 
table All.
Ill
Table All. The Inhibition of HTLV-III b y pyrophosphate analogues
Compound
0
II
R = -P(OH)2
Inhibition 
of HTLV-HI 
O jM)
Cell
Toxicity
(>JM)
0
II
R-----C------R
<30 >1000
RJ-R <30 >300
<30 >1000
V >100 -
R^ -C O ,H
>100 -
All.2 Discussion
All of the compounds tested were considerably less active, against 
the reverse transcriptase of HTLV-III, than phosphonoformic acid and do 
not show much promise for chemotherapeutic use. Phosphonoformic acid is 
readily taken up by bones and this small polar molecule does not readily 
cross cell walls; requiring incubation times of the order of 4h to 
achieve maximum cellular concentration (Stenberg, et al, 1985) . This is 
why a relatively high plasma concentration is needed for in vivo 
activity.
Carbonylbisphosphonic acid and ethenylidenebisphosphonic acid 
exhibit some activity but show cell toxicity in concentrations only 
10-00 times that of their IDso values. They also suffer from similar
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problems to phosphonoformic acid in that they are readily absorbed by 
bones (section 1.4.1) and have difficulty crossing cell walls (section 
1.4.2).
Benzene-1,2-bisphosphonic acid is the most promising of the 
compounds tested because although this molecule itself is no more 
effective than carbonylbisphosphdnic acid or ethenylidenebisphosphonic 
acid, the possibility exists for preparing a wide range ofsubstituted 
analogues. A lipophilic side chain could result in an increase in ease 
of cell uptake and reduced affinity for bones and teeth on steric 
grounds. More work needs to be done on this class of compound.
At present the most promising compound tested against the reverse 
transcriptase of HTLV-III is 3;-azido-37-deoxythymidine (AZT; Fig. 
All.2).
Fig. All.2 The structure of 3,-azido-3,-deoxythymidine
Under the conditions of the reverse transcriptase assay, AZT was 
active at concentrations as low as 0.03 jiM and AZT is currently 
undergoing clinical trials (Mitsuta, et al, 1985). It expresses low 
animal toxicity and can be given in relatively large doses.
It can be concluded that pyrophosphate analogues show little 
promise for the chemotherapy of AIDS relative to AZT but might still be 
useful in the chemotherapy of adventicious viral infections in these 
immunocompromised patients.
Note
The HTLV-III assays were kindly performed by Dr. Derek Kinchington 
(St. Mary's Hospital, London) to whom I must express my gratitude.
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APPENDIX III
BROAD SPECTRUM SCREEN OF TRIS (CYCLOHEXYLAMMONIUH) ETHENYLIDENE- 
BISPHOSPHONATE
The title compound was submitted to the USAMRIID (U.S. Army 
Medical Research Institute of Infectious Diseases, Frederick, Maryland, 
21701-5011, U.S.A.) screening program for evaluation of activity against 
a range of viruses. The results are listed in table AIII.
Table AIII Biological activity of tris (cyclohexylaranonium) 
ethenylidenebisphosphcnate against a range of viruses
VIRUS GENUS
I050
(ug/cm3)
“ S .
(ug/cm3)
THERAPUTIC
INDEX
Vesicular
stomatitis
Rhabdovirus - 100 0
Vaccina Poxvirus 505 320 63
Adenovirus 
(Type 2)
Adenovirus - 320 0
Venezuelan
equine
encephalomyelitis
Alphavirus 320 0
Sandfly
fever
(Sicilian)
Phlebovirus 755 100 13
a) Minimum concentration resulting in a 50% reduction in viable cells
AIII.1 Discussion
Tris(cyclohexylammonium) ethenylidenebisphosphonate appears to 
show little antiviral activity. This is in stark contrast to the 
activity of the similar carbonylbisphosphonic acid which is known to 
inhibit influenza (Cload and Hutchinson, 1983), herpes, hepatitis B
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(Oberg, 1983), HTLV-III (Vrang and Oberg, 1986) and avian myoloblastosis 
virus (AHV) (Eriksson, et al, 1982). Replacement of the electron 
withdrawing carbonyl group by a carbon-carbon double bond is also found 
to cause a loss of activity against influenza (table 7.6) where it has 
been found that substituted methylenebisphosphonates bearing electron 
withdrawing groups are more active, than those without (section 7.6). It 
is possible that the effectiveness of substituted methylene­
bisphosphonates in mimicking inorganic pyrophosphoric acid is important 
for other classes of viruses.
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